[
    {
        "id": "58",
        "PMID": "10547391",
        "title": "\nRandomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer",
        "journal": "J Natl Cancer Inst",
        "abstract": "Background:\nTreatment A has been shown to inhibit breast carcinogenesis in preclinical studies. We determined the efficacy of treatment A in preventing a second breast malignancy in women with breast cancer.\nMethods:\nWe randomly assigned 2972 women, aged 30\u201070 years, with surgically removed stage I breast cancer or ductal carcinoma in situ to receive for 5 years either treatment A orally (200 mg/day) (n=1496) or no treatment (n = 1476). Random assignment of patients was centrally managed by the coordinating center in Milan. All women were followed by use of the same procedures throughout the study period, and the radiologists who examined the mammograms were blinded to the allocated treatment arm. The primary end point was the incidence of contralateral breast cancer or ipsilateral breast cancer 7 years after randomization. The hazards of breast cancer occurrence were determined by Cox proportional hazards regression analysis. Statistical tests were two\u2010sided.\nResults:\n2867 assessable women were included in the analyses (1432 in the treatment A arm and 1435 in the control arm). At a median observation time of 97 months, there were no statistically significant differences in the occurrence of contralateral breast cancer (65 events in the treatment A arm versus 71 in the control arm; hazard ratio [HR] = 0.92; 95% confidence interval [CI] = 0.66\u20101.29; P = .642) or ipsilateral breast cancer (treatment A group = 100 events; control group = 121 events; HR = 0.83; 95% CI = 0.64\u20101.09; P = .177) between the two arms. There were no statistically significant differences between the two arms in tumors in other organs (38 in the treatment A arm versus 40 in the control arm), incidence of distant metastasis (HR = 0.98; 95% CI = 0.79\u20101.22; P = .858), and all\u2010cause mortality (HR = 1.16; 95% CI = 0.92\u20101.48; P = .215).\nConclusion:\nTreatment A was not more effective than no treatment in preventing a second breast malignancy in women with breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study where researchers looked at a special treatment for women who had breast cancer. They wanted to see if this treatment could help prevent the breast cancer from coming back in the other breast. They tested the treatment on 2972 women and followed them for 7 years.\n\nThe results showed that the treatment did not work very well in preventing the breast cancer from coming back. The study found that the treatment was not more effective than not getting the treatment at all in preventing a second breast malignancy.\n\nThe researchers looked at lots of different things, like how many women got breast cancer in the other breast, how many got cancer in other parts of their body, and how many died. They found that the treatment did not make a big difference in any of these things.\n\nSo, the study found that the treatment was not very effective in preventing breast cancer from coming back. It's important to remember that this study only looked at one specific treatment, and there may be other treatments that could be more effective.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "57",
        "PMID": "10547391",
        "title": "\nRandomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer",
        "journal": "J Natl Cancer Inst",
        "abstract": "Background:\nTreatment A has been shown to inhibit breast carcinogenesis in preclinical studies. We determined the efficacy of treatment A in preventing a second breast malignancy in women with breast cancer.\nMethods:\nWe randomly assigned 2972 women, aged 30\u201070 years, with surgically removed stage I breast cancer or ductal carcinoma in situ to receive for 5 years either treatment A orally (200 mg/day) or no treatment. The primary end point was the incidence of contralateral breast cancer or ipsilateral breast cancer 7 years after randomization. Other end points considered post hoc were the same outcomes stratified by menopausal status, incidence of distant metastases, overall mortality, and tumors in other organs. The hazards of breast cancer occurrence were determined by Cox proportional hazards regression analysis. Statistical tests were two\u2010sided.\nResults:\nAt a median observation time of 97 months, there were no statistically significant differences in the occurrence of contralateral breast cancer (P =.642) or ipsilateral breast cancer (P =.177) between the two arms. However, an interaction was detected between treatment A and menopausal status in both outcomes (P for interaction in both outcomes =.045), with a possible beneficial effect in premenopausal women (contralateral breast cancer: adjusted hazard ratio [HR] = 0.66, and 95% confidence interval [CI] = 0.41\u20101.07; ipsilateral breast cancer: adjusted HR = 0.65, and 95% CI = 0.46\u20100. 92) and an opposite effect in postmenopausal women (contralateral breast cancer: adjusted HR = 1.32, and 95% CI = 0.82\u20102.15; ipsilateral breast cancer: adjusted HR = 1.19, and 95% CI = 0.75\u20101. 89). There were no statistically significant differences between the two arms in tumors in other organs, incidence of distant metastasis, and all\u2010cause mortality.\nConclusion:\nTreatment A of women with breast cancer for 5 years appears to have no statistically significant effect on the incidence of second breast malignancies overall, although a possible benefit was detected in premenopausal women. These studies, particularly the post hoc analyses, are considered exploratory and need to be confirmed.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a special treatment could help prevent breast cancer from coming back in women who had breast cancer before. The treatment was given to a bunch of women for 5 years, and the researchers looked to see if it worked.\n\nThe results were a little tricky, but basically, the treatment didn't seem to make a big difference in whether the breast cancer came back in the other breast. But, the researchers found something interesting - the treatment might have helped prevent breast cancer from coming back in some women who were not yet menopausal.\n\nIt's important to remember that this study was just a small one, and more research needs to be done to confirm these findings. But, it's always good to learn about new ways to help prevent breast cancer, and this study gives us some things to think about for future research.\n\nSo, in short, the study didn't show that the treatment worked for everyone, but it might have helped some women in a certain group. More research is needed to know for sure!"
    },
    {
        "id": "46",
        "PMID": "10637238",
        "title": "Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nIt is uncertain whether treatment A provides additional benefit compared with chemotherapy alone. This trial was initiated to explore this question.\nPatients and methods:\nBetween January 1988 and December 1992, 231 patients with metastatic breast cancer were randomized to receive chemotherapy alone or treatment A + chemotherapy as front\u2010line therapy for metastatic breast cancer. Patients who experienced a complete response to induction therapy either received or did not receive maintenance treatment as a secondary randomization. The two end points of interest for this study were time to treatment failure (TTF) and survival time.\nResults:\nMedian survival was 30.0 months for chemotherapy alone and 29.3 months treatment A and chemotherapy, p=0.834. Time to treatment failure (TTF) was 13.4 months for patients who received treatment A + chemotherapy compared with 10.3 month for chemotherapy alone patients (P = .087). The response rates (complete response and partial response) was 69.2% of for patients who received chemotherapy alone and 68.9% for patients who received treatment A + chemotherapy, P =.99. There was no significant difference in toxicities seen between the two arms of the study. There were four lethal toxicities. Three infectious deaths occurred in patients receiving treatment A with chemotherapy.\nConclusion:\nIn patients with metastatic breast cancer, treatment A with chemotherapy was not more effective than chemotherapy alone.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a new treatment called \"treatment A\" works better than just getting chemotherapy to treat breast cancer that has spread to other parts of the body. The study looked at 231 patients who were divided into two groups: some got treatment A and chemotherapy, and some just got chemotherapy alone.\n\nThe study found that the two groups had similar survival times and times until the cancer came back. The response rates (meaning how many patients had their cancer go away or shrink) were also similar between the two groups. The only difference was that four patients in the treatment A group died from infections, but this was not enough to make a big difference in the overall results.\n\nSo, the study found that treatment A did not work any better than just getting chemotherapy alone to treat metastatic breast cancer. This means that doctors and patients should not use treatment A for this type of cancer unless there are other good reasons to use it.\n\nI hope this helps! Let me know if you have any questions or need further clarification."
    },
    {
        "id": "45",
        "PMID": "10637238",
        "title": "Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nIt is uncertain whether treatment A provides additional benefit compared with chemotherapy alone. This trial was initiated to explore this question.\nPatients and methods:\nBetween January 1988 and December 1992, 231 patients with estrogen receptor (ER)\u2010positive or ER\u2010unknown metastatic breast cancer were randomized to receive chemotherapy alone or treatment A + chemotherapy as front\u2010line therapy for metastatic breast cancer. Patients who experienced a complete response to induction therapy either received or did not receive maintenance treatment as a secondary randomization.\nResults:\nThe response rates (complete response and partial response) of patients who received chemotherapy alone and treatment A + chemotherapy were similar (69.2% v 68.9%, respectively; P =.99). Time to treatment failure (TTF) was slightly longer for patients who received treatment A + chemotherapy compared with chemotherapy alone patients (13.4 months v 10.3 months, respectively; P =.087), and TTF was significantly longer in ER\u2010positive compared with ER\u2010negative patients (17.4 months v 10.3 months, respectively; P =.048). However, ER status had no effect on overall survival (30.0 months for chemotherapy alone v 29.3 months for treatment A + chemotherapy).\nConclusion:\nIn patients with potentially hormone\u2010sensitive metastatic breast cancer, treatment A + chemotherapy prolongs TTF for ER\u2010positive patients without improving overall survival.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a new treatment called \"treatment A\" works better than just taking chemotherapy medicine to treat breast cancer that has spread to other parts of the body. The study looked at 231 patients who had breast cancer that was either sensitive to hormones or not sensitive to hormones.\n\nThe study found that the two groups of patients (those who got chemotherapy alone and those who got treatment A + chemotherapy) had similar results in terms of how well the cancer responded to the treatment. However, the patients who got treatment A + chemotherapy lived a little longer than the patients who just got chemotherapy.\n\nBut here's the thing: the study didn't find that the treatment made a big difference in how long the patients lived overall. So, while the treatment might be helpful for some patients, it's not a magic cure-all for breast cancer.\n\nNow, here's where things get a little tricky. The study authors tried to make the results sound more positive than they actually are. They did this by focusing on some of the results that were not statistically significant (meaning they could have happened by chance), and by ignoring other results that were not what they wanted to"
    },
    {
        "id": "27",
        "PMID": "11261827",
        "title": "Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer",
        "journal": "Breast Cancer Res Treat",
        "abstract": "Purpose:\nEfficacy and safety of treatment A was compared with comparator B in a group of postmenopausal women with advanced breast cancer, without previous systemic therapy for advanced breast cancer.\nMethods and materials:\nThe study was a prospective double\u2010blind randomized trial. All treated patients presented with positive estrogen receptors. Main end points were response rates, toxicity profile analysis, time to progression and survival. WHO and ECOG criteria were employed for response evaluation while toxicity was assessed according to WHO guidelines. Curves were constructed by means of Kaplan\u2010Meier methodology and were compared by means of log\u2010rank test.\nResults:\nFrom January 1996 to January 1999 a total of 217 patients were included in the study (106 in the treatment A and 111 in the comparator B). Both groups of patients were homogeneous regarding the main prognostic factors. A response rate of 64% (68/106) was observed in the treatment A group as compared with a 52% (58/111) in the comparator B group. Median times to progression and overall survival were not significantly different. A lower incidence of undesirable effects was appreciated in the treatment A arm.\nConclusion:\nOur data suggest that treatment A is an efficient and well\u2010tolerated agent for the therapy of postmenopausal women with hormonal positive receptors advanced breast cancer, and must be considered an alternative to comparator B as first line therapy for ER+ advanced breast cancer patients and as well as an adjuvant treatment.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help!\n\nSo, there was a big study done to see which treatment is best for women with breast cancer. The study compared two different treatments, called \"Treatment A\" and \"Comparator B.\" The researchers found out that the women who got Treatment A had a higher chance of getting better and had fewer side effects compared to the women who got Comparator B.\n\nBut here's the thing: the study didn't find a big difference between the two treatments, so the researchers had to look for other ways to make Treatment A sound better. They did this by focusing on some of the results that were a little better for Treatment A, and by ignoring some of the results that were worse for Treatment A.\n\nSo, even though the study didn't show that Treatment A is definitely better than Comparator B, the researchers are suggesting that it might be a good option for some people. But it's important to remember that this is just one study, and more research needs to be done to confirm these findings.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "28",
        "PMID": "11261827",
        "title": "Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer",
        "journal": "Breast Cancer Res Treat",
        "abstract": "Purpose:\nEfficacy and safety of treatment A was compared with comparator B in a group of postmenopausal women with advanced breast cancer, without previous systemic therapy for advanced breast cancer.\nMethods and materials:\nThe study was a prospective double\u2010blind randomized trial. All treated patients presented with positive estrogen receptors. Main end points were response rates, toxicity profile analysis, time to progression and survival. WHO and ECOG criteria were employed for response evaluation while toxicity was assessed according to WHO guidelines. Curves were constructed by means of Kaplan\u2010Meier methodology and were compared by means of log\u2010rank test.\nResults:\nFrom January 1996 to January 1999 a total of 217 patients were included in the study (106 in the treatment A and 111 in the comparator B). Both groups of patients were homogeneous regarding the main prognostic factors. Response rates were not statistically different between the two therapeutic arms. A response rate of 64% (68/106) was observed in the treatment A group as compared with a 52% (58/111) in the comparator B group. Median times to progression (hazard ratios (HR) = 1.016; 95% CI 0.80\u20101.32; p=0.823) and overall survival (HR = 0.97 (95% CI 0.74\u20101.29; p=0.532) were not statistically significantly different. A lower incidence of undesirable effects was appreciated in the treatment A arm.\nConclusion:\nTreatment A was not more effective than comparator B in postmenopausal women with advanced breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see which treatment is best for women with breast cancer that has spread to other parts of their body. The study compared two different treatments, and they looked at how well they worked and how safe they were. They found out that one of the treatments didn't work any better than the other one, and they didn't see any big differences in how safe they were.\n\nThe study looked at how many women responded to the treatment, how long it took for the cancer to grow again, and how long the women lived. They found that the two treatments were about the same in all of these areas.\n\nThe study also found that one of the treatments had fewer side effects than the other one. Side effects are things that can happen when you take medicine, like feeling sick or having a headache.\n\nSo, the study showed that one of the treatments is just as good as the other one, but it has fewer side effects. This means that doctors can use this treatment for women with breast cancer, and they don't have to worry as much about the side effects.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "34",
        "PMID": "12177098",
        "title": "Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nTo compare the efficacy and tolerability of treatment A with comparator B in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment.\nPatients and methods:\nIn this double\u2010blind, double\u2010dummy, parallel\u2010group study, postmenopausal patients were randomized to receive either treatment A or comparator B. The primary end point was time to progression (TTP). Secondary end points included time to treatment failure (TTF), objective response (OR) rate, duration of response (DOR), and tolerability.\nResults:\nPatients (n = 400) were followed for a median period of 16.8 months. Treatment A was not more effective than comparator B in terms of TTP (hazard ratio, 0.92; 95% confidence interval [CI], 0.74 to 1.14; P =.43); median TTP was 5.4 months with treatment A and 3.4 months with comparator B. There was no statistically significant difference between the 2 groups for TTF. Median TTF was 4.6 months for treatment A and 3.3 months for comparator B (HR, 0.96; 95% CI, 0.77 to 1.19; P = .69). At the time of this data analysis, the rate of deaths was respectively for treatment A and comparator B, 35.4% (n=73) vs. 33.5% (n=65). OR rates were 17.5% with both treatments. DOR was statistically significantly greater for treatment A compared with comparator B; the ratio of average response durations was 1.35 (95% CI, 1.10 to 1.67; P < 0.01). Both treatments were well tolerated.\nConclusion:\nTreatment A was not more effective than comparator B for postmenopausal women with advanced breast cancer whose disease progresses on tamoxifen therapy.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to compare two different treatments for breast cancer. The treatments were given to women who had breast cancer that had spread to other parts of their body. The study wanted to see which treatment was better at helping these women live longer without their cancer getting worse.\n\nThe study found that one of the treatments, called \"Treatment A,\" did not work any better than the other treatment, called \"Comparator B.\" Both treatments helped some women live longer, but there was no big difference between them.\n\nThe study also looked at how well the treatments worked in different groups of women, like those who were postmenopausal (meaning they had gone through menopause, which is when a woman's body stops making eggs) or those who had been on tamoxifen therapy (a type of medicine that helps stop the growth of some cancers).\n\nThe study found that one of the treatments, Treatment A, worked a little better than Comparator B for some of these groups of women. But overall, the two treatments were about the same.\n\nThe study was done to help doctors and patients make informed decisions about which treatment to use for breast cancer. And the results showed that Treatment A was not"
    },
    {
        "id": "33",
        "PMID": "12177098",
        "title": "Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nTo compare the efficacy and tolerability of treatment A with comparator B in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment.\nPatients and methods:\nIn this double\u2010blind, double\u2010dummy, parallel\u2010group study, postmenopausal patients were randomized to receive either treatment A or comparator B. The primary end point was time to progression (TTP). Secondary end points included objective response (OR) rate, duration of response (DOR), and tolerability.\nResults:\nPatients (n = 400) were followed for a median period of 16.8 months. Treatment A was as effective as comparator B in terms of TTP (hazard ratio, 0.92; 95% confidence interval [CI], 0.74 to 1.14; P =.43); median TTP was 5.4 months with treatment A and 3.4 months with comparator B. OR rates were 17.5% with both treatments. Clinical benefit rates (complete response + partial response + stable disease > or = 24 weeks) were 42.2% for treatment A and 36.1% for comparator B (95% CI, \u20104.00% to 16.41%; P =.26). In responding patients, median DOR (from randomization to progression) was 19.0 months for treatment A and 10.8 months for comparator B. Using all patients, DOR was significantly greater for treatment A compared with comparator B; the ratio of average response durations was 1.35 (95% CI, 1.10 to 1.67; P < 0.01). Both treatments were well tolerated.\nConclusion:\nTreatment A was at least as effective as comparator B, with efficacy end points slightly favoring treatment A. Treatment A represents an additional treatment option for postmenopausal women with advanced breast cancer whose disease progresses on tamoxifen therapy.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to compare two different treatments for breast cancer. The study looked at how well each treatment worked and how safe they were for women who had breast cancer that had spread to other parts of their body.\n\nThe study found that one of the treatments, called \"Treatment A,\" was almost as good as the other treatment, called \"Comparator B,\" at helping the cancer not grow or shrink. The study also found that Treatment A was slightly better at keeping the cancer from growing for a longer time.\n\nBut here's the thing: the study didn't find a big difference between the two treatments, so it's not like one of them was way better than the other. Both treatments seemed to work pretty well, but Treatment A might be a little bit better in some ways.\n\nThe study also found that both treatments were safe for the women who took them.\n\nSo, in summary, the study showed that Treatment A might be a good option for women with breast cancer that has spread to other parts of their body, but it's not a lot better than Comparator B. Both treatments seemed to work pretty well, but Treatment A might have a slight edge in some ways. And both"
    },
    {
        "id": "12",
        "PMID": "15947110",
        "title": "Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial",
        "journal": "Endocr Relat Cancer",
        "abstract": "This study was designed to address whether treatment A with chemotherapy provides additional activity compared with chemotherapy alone in breast cancer patients with operable or locally advanced disease. Between January 1997 and January 2002, 211 consecutive patients with T2\u20104, N0\u20101, M0 breast cancer were randomized to receive either epirubicin alone (EPI) (n=105) or epirubicin plus treatment A (n=106). The primary outcome was the overall response rate. Overall, 198 patients received the planned chemotherapy dose (99 patients (94.2%) in the EPI arm and 99 patients (93.4%) in the EPI+treatment A arm). There was no statistically significant difference in overall response rate between the two treatment arms (76 versus 82% in the EPI and EPI+treatment A arms respectively). Pathological complete response was documented respectively in EPI and EPI+treatment A in 5 (4.8%) and 7 (6.7%) patients, and respectively 3 (2.9%) and 6 (5.7%) patients had carcinoma in situ. Toxicity did not differ from that expected with epirubicin. Leukopenia was the most relevant side effect, with about 50% of patients experiencing grade III\u2010IV toxicity in both arms. Platelet toxicity was uncommon and mild. Grade II\u2010III hemoglobin was observed in 15% of patients. Diarrhea and mucositis from mild to moderate occurred in 10% of patients. Acute cardiac toxicity was absent in both arms. All these side effects, attributable to epirubicin, were equally distributed in both arms. Treatment A with chemotherapy was not more effective than chemotherapy alone in breast cancer patients with operable or locally advanced disease.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a special treatment called \"treatment A\" helps people with breast cancer. The study looked at 211 patients who had different types of breast cancer. Half of the patients got the special treatment, and the other half didn't. The researchers wanted to see if the treatment made the cancer go away faster or better.\n\nThey found out that the treatment didn't make a big difference in how well the cancer responded to the treatment. Both groups of patients had about the same amount of cancer go away. They also looked at how bad the side effects were, and they found that the patients in both groups had similar amounts of side effects, like feeling sick or having low blood cell counts.\n\nSo, the study found that the special treatment didn't work any better than the regular treatment that doctors usually give to people with breast cancer. It's important to remember that this study only looked at a small group of people, and more research needs to be done to see if the treatment works for everyone. But for now, doctors will keep using the regular treatment to help people with breast cancer.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "11",
        "PMID": "15947110",
        "title": "Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial",
        "journal": "Endocr Relat Cancer",
        "abstract": "This study was designed to address whether treatment A with chemotherapy provides additional activity compared with chemotherapy alone in breast cancer patients with operable or locally advanced disease. Between January 1997 and January 2002, 211 consecutive patients with T2\u20104, N0\u20101, M0 breast cancer were randomized to receive either epirubicin alone (EPI) or epirubicin plus treatment A. Ki67 expression was evaluated immunohistochemically in tumor specimens obtained before chemotherapy by incision biopsy and at definitive surgery. Tumor shrinkage of >50% was obtained in 76% of patients randomized in the EPI arm and 81.9% of patients randomized in the EPI+treatment A arm (not significant). The corresponding rates of clinical and pathological complete response were 20.2 and 21.9% (not significant), and 4.8 and 6.7% (not significant), respectively. Pathologically complete response was more frequently observed in estrogen receptor (ER)\u2010negative (ER\u2010) tumors (P=0.04) and correlated with elevated baseline Ki67 expression (P<0.01). Both EPI treatment and EPI+treatment A resulted in a significant reduction in Ki67 expression, either in overall patients (P=0.000) or in patients with ER+ breast cancer (P=0.000). The reduction in Ki67 immunostaining in the EPI+treatment A arm was greater than in the EPI arm, leading to a lower Ki67 expression at post\u2010operative residual histology (P=0.0041). The addition of treatment A to epirubicin chemotherapy did not improve the response rate but led to a significantly higher reduction in the Ki67 expression. Baseline elevated Ki67 expression and the ER\u2010 statuses were both associated with a greater chance of obtaining a pathological complete response at residual histology.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a special treatment called \"treatment A\" helps breast cancer patients get better. The study looked at 211 patients who had breast cancer that was either operable or had spread to nearby tissues. Half of the patients got a treatment called \"epirubicin\" alone, and the other half got both epirubicin and treatment A.\n\nThe researchers looked at the cancer cells under a microscope before and after the treatment to see if the cancer had shrunk. They found that about 76% of the patients who got epirubicin alone had their cancer shrink by more than half, and about 82% of the patients who got both epirubicin and treatment A had their cancer shrink by more than half.\n\nBut here's the interesting part: the researchers found that the patients who got treatment A had a bigger drop in the number of cancer cells compared to the patients who got epirubicin alone. In other words, treatment A helped the cancer cells die faster!\n\nThe researchers also looked at the cancer cells to see if they had a certain protein called \"Ki67\" on them. They found that the patients who got treatment A had fewer cancer"
    },
    {
        "id": "20",
        "PMID": "16148021",
        "title": "Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group",
        "journal": "Ann Oncol",
        "abstract": "Purpose:\nThe aim of this study was to explore the effect of dose\u2010dense sequential chemotherapy with or without treatment A primarily on disease\u2010free survival (DFS) and secondarily on overall survival (OS) in patients with high\u2010risk operable breast cancer.\nPatients and methods:\nFrom June 1997 until November 2000, 604 patients with T1\u20103N1M0 or T3N0M0 tumors were randomized to three cycles of epirubicin 110 mg/m2 followed by three cycles of treatment A followed by three cycles of 'intensified' CMF (cyclophosphamide 840 mg/m2, methotrexate 47 mg/m2 and fluorouracil 840 mg/m2) (group A), or to four cycles of epirubicin followed by four cycles of CMF, as in group A (group B). All cycles were given every 2 weeks with granulocyte colony\u2010stimulating factor support.\nResults:\nA total of 595 patients were eligible. Median follow\u2010up was 61.7 months for group A and 62 months for group B. DFS and OS did not differ significantly between treatment groups (log\u2010rank P = 0.55 and P = 0.38, respectively). The 3\u2010year DFS was 80% in group A and 77% in group B. Survival rates were 93% and 90%, respectively. Comparison of quality of life outcomes between the two groups showed no statistically significant differences. Both regimens were well tolerated and severe acute side\u2010effects were infrequent. No cases of severe cardiotoxicity or acute leukemia were recorded.\nConclusion:\nTreatment A with a dose\u2010dense sequential chemotherapy was not more effective than a dose\u2010dense sequential chemotherapy alone in patients with high\u2010risk operable breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a special kind of chemotherapy called \"treatment A\" could help people with breast cancer live longer and feel better. The study looked at 600 people with breast cancer and divided them into two groups. One group got three cycles of chemotherapy, and the other group got four cycles of chemotherapy. They both got the same medicines, but one group got them more often.\n\nThe study found that both groups did almost the same in terms of how long they lived and how they felt. They both lived for about the same amount of time and didn't have many side effects from the chemotherapy. The study showed that the special chemotherapy didn't work any better than the regular chemotherapy in helping people with breast cancer live longer and feel better.\n\nSo, the study didn't find any difference between the two groups, and the special chemotherapy didn't seem to help more than the regular chemotherapy. That's why the doctors didn't think it was necessary to use the special chemotherapy in this study.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "19",
        "PMID": "16148021",
        "title": "Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group",
        "journal": "Ann Oncol",
        "abstract": "Purpose:\nThe aim of this study was to explore the effect of dose\u2010dense sequential chemotherapy with or without treatment A primarily on disease\u2010free survival (DFS) and secondarily on overall survival (OS) in patients with high\u2010risk operable breast cancer.\nPatients and methods:\nFrom June 1997 until November 2000, 604 patients with T1\u20103N1M0 or T3N0M0 tumors were randomized to three cycles of epirubicin 110 mg/m2 followed by three cycles of treatment A followed by three cycles of 'intensified' CMF (cyclophosphamide 840 mg/m2, methotrexate 47 mg/m2 and fluorouracil 840 mg/m2) (group A), or to four cycles of epirubicin followed by four cycles of CMF, as in group A (group B). All cycles were given every 2 weeks with granulocyte colony\u2010stimulating factor support.\nResults:\nA total of 595 patients were eligible. Median follow\u2010up was 61.7 months for group A and 62 months for group B. The 3\u2010year DFS was 80% in group A and 77% in group B. Survival rates were 93% and 90%, respectively. The effect of treatment on the hazard of death was different according to hormonal receptor status. More specifically, in patients with negative receptor status the hazard of death was significantly higher for group B (hazard ratio 2.42). Both regimens were well tolerated and severe acute side\u2010effects were infrequent. No cases of severe cardiotoxicity or acute leukemia were recorded.\nConclusion:\nThe present study failed to demonstrate a significant difference in DFS or OS between the two treatment groups. However, our study has shown clearly that treatment A can be safely incorporated to dose\u2010dense sequential chemotherapy.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help!\n\nSo, there was a big study done to see if a new treatment for breast cancer works better than another treatment. The study looked at 600 women with breast cancer and divided them into two groups. One group got one treatment, and the other group got a different treatment. The researchers wanted to see if the second treatment helped the women live longer without the cancer coming back.\n\nThe study found that the two treatments were about the same in terms of how well they worked. But, the researchers also found that one of the treatments was safer than the other. They didn't see any cases of serious side effects like heart problems or leukemia in the group that got the safer treatment.\n\nSo, even though the treatments didn't work differently, the researchers are happy that they found a way to make the second treatment safer for patients. This means that doctors can use this treatment in their practice and feel more confident that it will be safe for their patients.\n\nIn summary, the study found that two different treatments for breast cancer are about the same in terms of how well they work, but one of them is safer than the other."
    },
    {
        "id": "51",
        "PMID": "16314619",
        "title": "Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nTo determine whether treatment A, improves survival in patients with brain metastases when used as an adjunct to whole\u2010brain radiation therapy (WBRT).\nPatients and methods:\nPatients with brain metastases from solid tumors and a Karnofsky performance score of > or = 70 were randomly assigned to receive WBRT with supplemental oxygen and either treatment A (treatment A arm) or no treatment (control arm). The primary end point was survival.\nResults:\nThe study consisted of 515 eligible patients (treatment A arm, n = 265; control arm, n = 250). The median survival time (MST) was 5.4 months for the treatment A arm versus 4.4 months for the control arm (hazard ratio [HR] = 0.87; P = .16). For the subgroup of patients with non\u2010small\u2010cell lung cancer (NSCLC) or breast cancer, the MST was 6.0 and 4.4 months, respectively (HR = 0.82; P = .07). Cox multiple regression analysis demonstrated a significant reduction in the risk of death for the treatment A arm in both primary populations. Further analysis indicated that the benefit may be restricted to the subgroup of patients with breast cancer. Response rates (radiographic complete response plus partial response) improved by 7% (P = .10) and 13% (P = .01) for all patients and for NSCLC and breast cancer patients in the treatment A arm, respectively. The most common severe adverse event in patients treated with treatment A was hypoxemia, which was reversible and effectively managed with supplemental oxygen in most patients.\nConclusion:\nThe addition of treatment A to WBRT may improve response rates and survival in patients with brain metastases, particularly metastases from breast cancer. A confirmatory trial for breast cancer patients has been initiated.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a new treatment called \"treatment A\" can help people with cancer in their brains. The treatment was added to a different treatment called \"whole-brain radiation therapy\" (WBRT), which is already used to try to make the cancer go away.\n\nThe study found that when treatment A was added to WBRT, some people with cancer in their brains lived longer than those who didn't get the extra treatment. Specifically, the people who got treatment A lived for about 5.4 months on average, while the people who didn't get it lived for about 4.4 months on average.\n\nThe study also found that the benefit of treatment A was only seen in people with cancer that started in their breasts. For people with cancer in other parts of their body, the treatment didn't seem to make much of a difference.\n\nIt's important to note that this study was done on a small group of people, and more research needs to be done to confirm these findings. But overall, the study suggests that treatment A might be a helpful addition to WBRT for some people with brain cancer.\n\nNow, I know this might be a lot to take in, but I hope this summary"
    },
    {
        "id": "52",
        "PMID": "16314619",
        "title": "Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nTo determine whether treatment A, improves survival in patients with brain metastases when used as an adjunct to whole\u2010brain radiation therapy (WBRT).\nPatients and methods:\nPatients with brain metastases from solid tumors and a Karnofsky performance score of > or = 70 were randomly assigned to receive WBRT with supplemental oxygen and either treatment A (treatment A arm) or no treatment (control arm). The primary end point was survival.\nResults:\nThe study consisted of 515 eligible patients (treatment A arm, n = 265; control arm, n = 250). The median survival time (MST) was 5.4 months for the treatment A arm versus 4.4 months for the control arm (hazard ratio [HR] = 0.87; P = .16). There was no statistically significant difference between the 2 groups for response rate (complete plus partial response) (46% for the treatment A arm and 38% for the control arm; P = .10). There was not a statistically significant difference in the cumulative incidence at 1 year after random assignment of radiographic (21% treatment A vs. 18% control; p=0.53) or clinical progression (49% treatment A vs. 51% control; p = 0.49) in the brain between the treatment groups. At 6 months, respectively 16% and 15% of the patients had a stable or improving quality of life in treatment A arm and control arm. The most common severe adverse event in patients treated with treatment A was hypoxemia.\nConclusion:\nThe addition of treatment A to WBRT was not more effective than WBRT alone in patients with brain metastases.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a special treatment called \"treatment A\" helps people with cancer in their brains. The treatment was given to some people and not given to others, and the researchers looked at how well the treatment worked.\n\nThe results showed that the treatment didn't really help the people with cancer live longer or feel better. In fact, the people who got the treatment didn't do any better than the people who didn't get the treatment.\n\nThe researchers looked at lots of different things to see if the treatment made a difference, but they found that it didn't. They also looked at how well the patients were doing overall, and they found that the patients who got the treatment didn't do any worse than the patients who didn't get the treatment.\n\nSo, the study found that the special treatment didn't help people with cancer in their brains, and it's not something that doctors should use to try to help their patients.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "37",
        "PMID": "16504757",
        "title": "A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results",
        "journal": "Int J Radiat Oncol Biol Phys",
        "abstract": "Purpose:\nTo compare treatment A and comparator B in node\u2010positive, operable breast cancer patients.\nMethods and materials:\nThis was a randomized, multicenter, phase III trial enrolling 638 eligible women with prior breast surgery and positive axillary dissection. Patients in Arm A received treatment A, with concomitant radiotherapy (50 Gy +/\u2010 10\u201020\u2010Gy boost). Patients in Arm B received comparator B, with subsequent radiotherapy.\nResults:\nMedian treatment durations were 64 and 126 days (Arms A and B, respectively), with no significant difference in overall or disease\u2010free survival. Five\u2010year locoregional relapse\u2010free survival favored patients with conservative surgery (two thirds of the population), with less local and / or regional recurrence in Arm A than in Arm B (3% vs. 9%; p = 0.01). Multivariate analysis in this subgroup showed a 2.8\u2010fold increased risk of locoregional recurrence with comparator B, independent of other prognostic factors (p = 0.027). Febrile neutropenia and Grade 3\u20104 leukopenia were significantly more frequent in Arm A. Subclinical left ventricular ejection fraction events at 1 year were more frequent with treatment A (p = 0.02).\nConclusion:\nTreatment A has significantly better locoregional control in node\u2010positive breast cancer after conservative surgery and 50% shorter treatment, albeit with slightly more acute toxicity.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to compare two different treatments for breast cancer. The treatments were given to 638 women who had breast surgery and some of their lymph nodes removed. The women were divided into two groups: one group got treatment A, and the other group got treatment B.\n\nThe study found that the women who got treatment A had better control over their cancer and fewer side effects than the women who got treatment B. The women who got treatment A also had their cancer treated for shorter amount of time than the women who got treatment B.\n\nHowever, the study also found that the women who got treatment A had more mild side effects, like feeling tired or having a low white blood cell count. So, while treatment A seemed to work better for the women who got it, there were some extra side effects to consider.\n\nOverall, the study showed that treatment A might be a better option for some women with breast cancer, but it's important to talk to a doctor to figure out which treatment is best for each individual person.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "38",
        "PMID": "16504757",
        "title": "A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results",
        "journal": "Int J Radiat Oncol Biol Phys",
        "abstract": "Purpose:\nTo compare treatment A and comparator B in node\u2010positive, operable breast cancer patients.\nMethods and materials:\nThis was a randomized, multicenter, phase III trial enrolling 638 eligible women with prior breast surgery and positive axillary dissection. Patients in Arm A received treatment A, with concomitant radiotherapy (50 Gy +/\u2010 10\u201020\u2010Gy boost). Patients in Arm B received comparator B, with subsequent radiotherapy. The primary outcome was disease free survival.\nResults:\n650 women were enrolled in this trial, and a total of 638 patients were treated. Median treatment durations were 64 and 126 days (Arms A and B, respectively). Five\u2010year DFS in Arm A was 83% and in Arm B 79%, p = 0.22. Disease\u2010specific survival at 5 years was not statistically significantly different between Arm A and Arm B. Sixty\u2010eight patients died 34 in each group. There was no statistically significant difference at 5 years for regional or metastatic relapses. Local recurrences at 5 years was 3% in Arm A and 7% in Arm B, p=0.047). Febrile neutropenia (n=10 in arm A vs. n=1 in arm B) and Grade 3\u20104 leukopenia (n=43 vs n=4) were statistically significantly more frequent in Arm A. Subclinical left ventricular ejection fraction events at 1 year were more frequent with treatment A (p=0.02).\nConclusion:\nTreatment A was not more effective than comparator B in node\u2010positive, operable breast cancer patients.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to compare two different treatments for breast cancer. The study looked at 650 women who had breast cancer and had their surgery removed. Half of the women got one treatment, and the other half got another treatment. The researchers wanted to see which treatment worked better.\n\nThey found out that the two treatments didn't really differ much in terms of how well they worked. Both treatments helped most of the women (around 80%) stay cancer-free for at least five years. But there were a few differences in the side effects of the two treatments. Some women who got one treatment had more problems with their blood cells, and a few had heart problems.\n\nOverall, the study found that the two treatments were pretty similar in terms of how well they worked, but one of them had more side effects. It's important to remember that this study only looked at a small group of people, so more research might be needed to confirm these findings and to see if the treatments are safe and effective for everyone.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "32",
        "PMID": "17134892",
        "title": "Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group",
        "journal": "Eur J Cancer",
        "abstract": "Background:\nThe contribution of treatment A in breast cancer patients after receiving adjuvant chemotherapy is not fully established. We investigated the impact of treatment A, given sequentially after completion of adjuvant chemotherapy in patients with operable breast cancer.\nPatients and methods:\nBetween March 1991 and June 1999, 1863 women with stages I\u2010IIIA operable breast cancer who had undergone surgery and completed six cycles of adjuvant combination chemotherapy with either CMF, CAF, CEF, FAC or FEC were randomized to receive either treatment A for 3 years or no further treatment. Irrespective of menstrual status and hormone receptor content of the primary tumor, patients were stratified by institute, chemotherapy scheme and age (above 50 years or younger). The main end\u2010point was to detect a 5% increase in the 5 year survival (from 80% to 85%) in favor of treatment A. Secondary end\u2010 points were relapse free survival (RFS), local control, incidence of second primary breast cancer.\nResults:\nAfter exclusion of all patients from three sites because of inadequate documentation, a total of 1724 patients (93%) were analyzed (Treatment A 861 and Control 863). At a median follow\u2010up of 6.5 years, 396 deaths (23%) and 602 RFS events (35%) (relapse and/or death) have been observed. There was no statistically significant difference in survival between patients who were randomized to receive treatment A for 3 years and those who were randomized to no further treatment (HR 0.97; 95% CI, 0.79\u20101.18; p = 0.7377 by log\u2010rank test). At a median follow\u2010up of 6.5 years, 5\u2010year RFS on treatment A was 73% versus 67% in controls (p=0.035). Thirty eight patients (4.4%) in the treatment A arm discontinued treatment because of toxicity. The most common reasons for discontinuation were hot flashes (n = 8), vaginal bleeding (n = 7), weight gain (n = 4) and nausea (n = 4).\nConclusion:\nTreatment A in breast cancer patients after receiving adjuvant chemotherapy was not more effective than no treatment on overall survival.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a special treatment helps people with breast cancer live longer. The treatment was given to some people after they finished their chemotherapy, and the doctors wanted to see if it made a difference in how long they lived. They looked at how many people died or had their cancer come back, and they found out that the treatment didn't really make a big difference in how long they lived.\n\nBut, the doctors did find that some people had a little bit of trouble with side effects from the treatment, like hot flashes or vaginal bleeding. So, the doctors are still trying to figure out if this treatment is really helpful for people with breast cancer.\n\nOverall, the study showed that the treatment didn't make a big difference in how long people with breast cancer lived, but it's still important to do more research to see if it might be helpful in the future."
    },
    {
        "id": "31",
        "PMID": "17134892",
        "title": "Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group",
        "journal": "Eur J Cancer",
        "abstract": "Background:\nThe contribution of treatment A in breast cancer patients after receiving adjuvant chemotherapy is not fully established. We investigated the impact of treatment A, given sequentially after completion of adjuvant chemotherapy in patients with operable breast cancer.\nPatients and methods:\nBetween March 1991 and June 1999, 1863 women with stages I\u2010IIIA operable breast cancer who had undergone surgery and completed six cycles of adjuvant combination chemotherapy with either CMF, CAF, CEF, FAC or FEC were randomised to receive either treatment A for 3 years or no further treatment. Irrespective of menstrual status and hormone receptor content of the primary tumour, patients were stratified by institute, chemotherapy scheme and age (above 50 years or younger). The main end\u2010point was to detect a 5% increase in the 5 year survival (from 80% to 85%) in favour of treatment A. Secondary end\u2010 points were relapse free survival (RFS), local control, incidence of second primary breast cancer and correlation of results with hormone receptor content.\nResults:\nAfter exclusion of all patients from three sites because of inadequate documentation, a total of 1724 patients (93%) were analyzed (Treatment A 861 and Control 863). At a median follow\u2010up of 6.5 years, 5\u2010year RFS on treatment A was 73% versus 67% in controls (p=0.035). No difference was seen in overall survival. The benefit of treatment A was mainly seen in the subgroup of patients with histologically documented positive axillary nodes (5\u2010year RFS on treatment A 71% versus 64% in the control group, p=0.044) and in patients with tumours expressing the ER and PR positive phenotype (5\u2010year RFS on treatment A 77% versus 70% in the control group, p=0.014).\nConclusion:\nTreatment A administered for 3 years after completion of adjuvant chemotherapy in this otherwise unselected group of patients for endocrine sensitivity had a limited impact on relapse and had no detectable effect on overall survival. The beneficial effect of treatment A is mainly confined to the subgroup of patients with node\u2010positive disease and to patients with tumours expressing the ER and PR positive phenotype.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a special treatment helps people with breast cancer live longer. The treatment was given to some people after they finished their chemotherapy, and the doctors wanted to see if it made a difference in how long they lived.\n\nThe study found that the treatment didn't really help most people live longer. It only helped a little bit for some people who had cancer in their lymph nodes or who had certain kinds of cancer. The doctors think that the treatment might be helpful for those specific groups of people, but it's not helpful for most people with breast cancer.\n\nThe doctors also looked at the overall survival of the people in the study, which means how long they lived overall. They found that the treatment didn't really make a difference in how long they lived.\n\nSo, the study showed that the treatment doesn't seem to help most people with breast cancer live longer. But, it might be helpful for some people with certain types of cancer. It's important to talk to a doctor to figure out the best treatment plan for you or your loved one.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "1",
        "PMID": "17173959",
        "title": "Effective cervical neoplasia detection with a novel optical detection system: a randomized trial",
        "journal": "Gynecol Oncol",
        "abstract": "Objective:\nTo assess whether the use of intervention A as an adjunct to colposcopy increases the detection of biopsy confirmed CIN 2, 3 (high grade cervical intraepithelial neoplasia).\nMethods:\nThis is a multicenter two\u2010arm randomized trial comparing colposcopy alone with colposcopy plus intervention A. Patients were recruited from 13 colposcopy clinics in a variety of practice settings. 2299 women referred for the evaluation of an abnormal cervical cytology were randomized with stratification by cytology; subsequently 113 women were excluded for a variety of reasons. The main study outcomes were differences in true\u2010positive rates (CIN 2, 3 and cancer identified) and false\u2010positive rates between the study arms.\nResults:\nThe true\u2010positive (TP) rates were 14.4% vs. 11.4% (p=0.035, one\u2010sided) for the combined colposcopy and intervention A arm compared to colposcopy\u2010only arm, respectively, in women with either an atypical squamous cell (ASC) or low\u2010grade squamous intraepithelial lesion (LSIL) cytology result. TP rates were similar between the two arms among women referred for the evaluation of HSIL (high\u2010grade squamous intraepithelial lesion). The 26.5% gain in true\u2010positives observed with the use of intervention A and colposcopy among women referred for an ASC or LSIL cytology was achieved with only a fractional increase in number of biopsies obtained per patient (0.30) and a modest increase in false\u2010positive rate\n(4%). In the combined colposcopy and intervention A arm among women with ASC or LSIL, the PPV (positive predictive value) of biopsies indicated by ntervention A was 15.0% and the PPV of biopsies indicated by colposcopy was 15.2%. Joint hypothesis testing indicates that intervention A and colposcopy provides benefit compared to colposcopy alone among women with ASC or LSIL.\nConclusion:\nCombining intervention A with colposcopy provides a clinically meaningful increase in the detection of CIN 2, 3 in women referred for the evaluation of mildly abnormal cytology results.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help!\n\nSo, there was a big study done to see if a new treatment called \"intervention A\" helps doctors find cervical cancer better. The study looked at 2,299 women who had some abnormal cells in their cervix. Half of these women got the new treatment, and the other half just got a regular check-up.\n\nThe study found that the women who got the new treatment were more likely to have their cervical cancer detected. Specifically, 14.4% of the women who got the new treatment had cervical cancer, compared to 11.4% of the women who just got a regular check-up. That means that the new treatment found about 2.5 more cases of cervical cancer for every 100 women treated.\n\nHowever, the study also found that the new treatment didn't make a big difference for all women. Only a small group of women with abnormal cells in their cervix actually had their cancer detected. So, the study suggests that the new treatment might be helpful for some women, but it's not a guarantee that all women will have their cancer detected.\n\nOverall, the study shows that the new treatment might be a useful tool for doctors to use when checking for cervical cancer. But more research is needed to know for sure if it'"
    },
    {
        "id": "2",
        "PMID": "17173959",
        "title": "Effective cervical neoplasia detection with a novel optical detection system: a randomized trial",
        "journal": "Gynecol Oncol",
        "abstract": "Objective:\nTo assess whether the use of intervention A as an adjunct to colposcopy increases the detection of biopsy confirmed CIN 2,3 (high grade cervical intraepithelial neoplasia).\nMethods:\nThis is a multicenter two\u2010arm randomized trial comparing colposcopy alone with colposcopy plus intervention A. Patients were recruited from 13 colposcopy clinics in a variety of practice settings. 2299 women referred for the evaluation of an abnormal cervical cytology were randomized with stratification by cytology; subsequently 113 women were excluded for a variety of reasons. The main study outcomes were differences in true\u2010positive rates (biopsy confirmed CIN 2, 3 and cancer) and false\u2010positive rates (all women having at least one cervical biopsy taken with none of the biopies diagnosed as CIN 2,3, or cancer) between the study arms.\nResults:\nThe final analyzed populations were 1096 in the colposcopy only arm and 1090 in the colposcopy plus intervention A arm. There was no statistically significant difference in the true positive rate between the 2 groups. The true positive rate was 19.9% (218/1096) in the colposcopy\u2010only arm vs 21.8% (238/1090) in the colposcopy plus intervention A arm; p=0.143. The false positive rate was 57.4% (629/1096) in the colposcopy\u2010only arm vs 60.5% (659/1090) in the colposcopy plus intervention A arm. No biopsy was performed in 239 (27.4%) in the colposcopy\u2010only arm and 193 (17.7%) in the colposcopy plus intervention A arm. The average number of biopsies was 1.03 for the colposcopy\u2010only arm and 1.30 for the colposcopy plus intervention A arm. Four subjects experienced minor adverse events during the study in both arms.\nConclusion:\nCombining intervention A with colposcopy was not more effective than colposcopy alone for the detection of CIN 2, 3 in women referred for the evaluation of mildly abnormal cytology results.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study where researchers looked at how well a special treatment called \"intervention A\" works when used with a test called colposcopy to find cervical cancer. They studied 2,299 women who had some abnormal cells in their cervix and were at risk of getting cancer.\n\nThe researchers found out that the treatment didn't make a big difference in how well the colposcopy test worked. Both groups of women (those who got the treatment and those who didn't) had about the same number of abnormal cells found.\n\nThe researchers also looked at how many women had to have a biopsy (a small surgery to remove some tissue from the cervix) to confirm if they had cancer. They found that about the same number of women in both groups had to have a biopsy.\n\nOverall, the study found that the treatment didn't make a big difference in how well the colposcopy test worked, and it's still a good test to use to check for cervical cancer.\n\nSo, the study didn't find any big benefits to using the treatment, but it's still a useful test to use to check for cancer. Does that make sense?"
    },
    {
        "id": "39",
        "PMID": "17179098",
        "title": "Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nTo evaluate the efficacy and tolerability of treatment A plus cyclophosphamide, doxorubicin, and fluorouracil (CAF) therapy in comparison with CAF alone, in patients with advanced or recurrent breast cancer.\nMethods and materials:\nIn this randomized, double\u2010blind, placebo\u2010controlled trial, patients were treated with six cycles of CAF therapy: 28 days/cycle, with doxorubicin (25 mg/m2) and fluorouracil (500 mg/m2) administered on days 1 and 8 and cyclophosphamide (100 mg orally [PO]) administered on day 1 through 14. Primary end point was overall response rate (ORR; partial or complete response). In total, 221 patients were assessable.\nResults:\nORR was 42.6% for CAF compared with 53.1% for treatment A + CAF, a 24.6% relative improvement and 10.5% absolute increase (P = .077). There was a trend for prolonged progression\u2010free survival (PFS; median 241 days for CAF v 366 days for treatment A + CAF; P = .145). In retrospectively defined subgroups, significant improvement in PFS in favor of treatment A was observed in patients who were premenopausal, had no prior therapy, and were stage IV at diagnosis with an intact primary tumor. Except for neutropenia and leukopenia, there was no statistically significant excess of grade 3/4 adverse events compared with CAF. Treatment with treatment A did not affect the plasma concentration of doxorubicin.\nConclusion:\nTreatment A + CAF was well tolerated and is suggested to have efficacy in patients who had not received prior therapy.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a new treatment called \"treatment A\" works better than a different treatment called \"CAF\" for people with breast cancer. The researchers wanted to know if treatment A is better at making the cancer go away and staying away.\n\nThey did a big experiment where they gave some people treatment A and some people CAF, and they looked at how well they worked. They found out that treatment A worked a little bit better than CAF, but not by a lot. They also found that treatment A was easier on the body and didn't make people feel as sick as CAF did.\n\nBut here's the thing: the researchers wanted to make treatment A look better than it really is, so they only talked about the good things about it and left out some of the not-so-good things. They wanted to make it seem like treatment A is a miracle cure, but it's not quite that simple.\n\nSo, even though treatment A might be a little bit better than CAF, we can't be sure because the researchers were trying to make it look better than it really is. We need to be careful and look at all the information before we can say for sure which treatment is best.\n\nDoes"
    },
    {
        "id": "40",
        "PMID": "17179098",
        "title": "Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nTo evaluate the efficacy and tolerability of treatment A plus cyclophosphamide, doxorubicin, and fluorouracil (CAF) therapy in comparison with CAF + placebo, in patients with advanced or recurrent breast cancer.\nMethods and materials:\nIn this randomized, double\u2010blind, placebo\u2010controlled trial, patients were treated with six cycles of CAF therapy: 28 days/cycle, with doxorubicin (25 mg/m2) and fluorouracil (500 mg/m2) administered on days 1 and 8 and cyclophosphamide (100 mg orally [PO]) administered on day 1 through 14. Primary end point was overall response rate (ORR; partial or complete response). In total, 221 patients were assessable.\nResults:\nA total of 227 patients were recruited, the full analysis set consisted of 221 patients. ORR was 42.6% (95% confidence interval (CI), 33.1 to 52.5) for CAF + placebo compared with 53.1% (95% CI, 43.5 to 62.5) for treatment A + CAF (P = .077). The median progression\u2010free survival (PFS) was 241 days for CAF + placebo v 366 days for treatment A + CAF; P = .145. Any adverse event occurred more frequently with CAF + treatment A, 95.5% vs. 88.4%, p=0.025. Neutropenia occurred for 91.2% with CAF + treatment A vs 77.7% with CAF + placebo, p=0.005. Treatment with treatment A did not affect the plasma concentration of doxorubicin.\nConclusion:\nTreatment A + CAF was not more effective than CAF + placebo in patients with advanced or recurrent breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a new treatment called \"treatment A\" was better than another treatment called \"CAF\" for people with breast cancer. The study involved 227 people who were randomly divided into two groups: one group got the new treatment A plus the old treatment CAF, and the other group got just the old treatment CAF.\n\nThe researchers looked at how well the treatments worked by measuring how many people had a good response to the treatment (like their cancer getting smaller or going away). They also looked at how long the cancer stayed away after treatment.\n\nThe results showed that the group that got treatment A plus CAF didn't do any better than the group that just got CAF. In fact, the group that got CAF plus treatment A had a slightly longer time before their cancer came back.\n\nThe researchers also looked at how often people in both groups had side effects from the treatments. They found that the group that got treatment A plus CAF had more side effects than the group that just got CAF.\n\nSo, the study found that treatment A plus CAF wasn't any better than just getting CAF for people with breast cancer. And, the group that got treatment A plus CAF had more side effects"
    },
    {
        "id": "53",
        "PMID": "17264336",
        "title": "Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nIn 1996, we initiated the multicenter phase III randomized trial to compare the effect on disease\u2010free survival (DFS) of experimental treatment A versus comparator B after breast\u2010conserving surgery for stages I and II breast cancer. This report presents the clinical results with a median follow\u2010up of 60 months.\nPatients and methods:\nBetween February 1996 and April 2000, 716 patients were entered onto this trial. Adjuvant treatment began within 6 weeks after surgery.\nResults:\nThere was no statistically significant difference in treatment in the 5\u2010year DFS (80% in both groups; P = .83), locoregional recurrence\u2010free survival (LRFS; 92% in comparator B v 95% in treatment A; P = .76), metastasis\u2010free survival (87% in comparator B v 84% in treatment A; P = .55), or overall survival (90% in comparator B v 91% in treatment A; P = .76). Nevertheless, in the node\u2010positive subgroup, the 5\u2010year LRFS was statistically better in the treatment A arm (97% in treatment A v 91% in comparator B; P = .02), corresponding to a risk of locoregional recurrence decreased by 39% (hazard ratio, 0.61; 95% CI, 0.38 to 0.93).\nConclusion:\nThis treatment protocol remains an appealing clinical option for many women with operable breast cancer at a high risk of recurrence. Combination treatments with new drugs for breast cancer are warranted.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see which treatment is best for women with breast cancer. The study looked at two different treatments and how well they worked. The results showed that one of the treatments didn't do much better than the other treatment. But, when they looked at a special group of women who had cancer in their lymph nodes, they found that one of the treatments did a bit better than the other.\n\nThe study is important because it helps doctors figure out which treatments are best for women with breast cancer. Even though one of the treatments didn't do much better than the other, the study showed that it's still a good option for some women. And, it showed that doctors should keep looking for new treatments to help more women with breast cancer.\n\nSo, in short, the study found that one of the treatments for breast cancer worked a bit better for women with cancer in their lymph nodes, but the other treatment is still a good option for many women."
    },
    {
        "id": "54",
        "PMID": "17264336",
        "title": "Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nIn 1996, we initiated the multicenter phase III randomized trial to compare the effect on disease\u2010free survival (DFS) of experimental treatment A versus comparator B after breast\u2010conserving surgery for stages I and II breast cancer. This report presents the clinical results with a median follow\u2010up of 60 months.\nPatients and methods:\nBetween February 1996 and April 2000, 716 patients were entered onto this trial (358 randomized to comparator B and 358 to treatment A) and respectively 343 and 352 patients were included in the analysis. Adjuvant treatment began within 6 weeks after surgery. The primary endpoint was disease\u2010free survival (DFS) defined as the time from randomization to the first treatment failure (in the ipsilateral breast, in the axillary/infraclavicular/IMCs, or at a distant site) or death (if no recurrence had been noted).\nResults:\nThere was no statistically significant difference in treatment in the 5\u2010year DFS (80% in both groups; P = .83), locoregional recurrence\u2010free survival (LRFS; 92% in comparator B v 95% in treatment A; P = .76), metastasis\u2010free survival (87% in comparator B v 84% in treatment A; P = .55), or overall survival (90% in comparator B v 91% in treatment A; P = .76).\nConclusion:\nTreatment A was not more effective than comparator B after breast\u2010conserving surgery for stages I and II breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see which treatment is better for people with breast cancer. The study looked at two different treatments, called \"Treatment A\" and \"Comparator B.\" The researchers wanted to know if Treatment A was more effective than Comparator B after surgery to remove the tumor.\n\nThey looked at the results of 716 patients who were in the study, and they found out that there was no big difference between the two treatments. Both treatments worked pretty well, and most of the patients (around 80%) were still cancer-free after 5 years.\n\nThe researchers also looked at other things, like how many patients had cancer come back in their breast or in other parts of their body, and they found that there was no big difference between the two treatments again.\n\nSo, the study found that Treatment A and Comparator B are pretty similar in terms of how well they work after breast cancer surgery. The researchers think that this is important information for doctors and patients to know when deciding which treatment to use.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "4",
        "PMID": "17530429",
        "title": "Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis",
        "journal": "Breast Cancer Res Treat",
        "abstract": "The randomized multicenter study on rapidly proliferating breast cancer was activated at the end of the 1980s. The present work investigated whether and to what degree the short\u2010term advantages observed from treatment A were maintained at a longer follow\u2010up. Two hundred and eighty\u2010one patients with node\u2010negative and high TLI tumors were randomized to receive treatment A or no further treatment. Overall, at a median follow\u2010up of 12 years, 99 relapses have been observed, 55 in the control arm and 44 in the treatment A arm. At a median follow\u2010up of 12 years, there was no statistically significant difference between treatment A and no treatment for the cumulative incidence of relapse, Hazard Ratio (HR) [95% confidence interval] = 0.75 [0.50\u20101.13]; p= 0.17 and for the cumulative incidence of death HR = 0.80 [0.48\u20101.33], p= 0.38. The incidence of contralateral tumors was similar in the two arms (10 vs. 11). Treatment A was not more effective than no treatment on rapidly proliferating breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done on cancer treatment. The study looked at how well a certain treatment worked on breast cancer that grows quickly. The researchers divided the patients into two groups: one group got the treatment, and the other group didn't get the treatment. They followed the patients for 12 years and looked at how many of them got better or worse.\n\nThe results showed that the treatment didn't really help the patients get better faster. In fact, the two groups were about the same in terms of how many patients got better or worse. The researchers also looked at how many patients had cancer in the other breast and found that it was about the same in both groups.\n\nSo, the study found that the treatment didn't work any better than doing nothing for breast cancer that grows quickly. It's important to remember that this is just one study, and there are many other things to consider when looking at cancer treatment. But overall, this study suggests that this particular treatment might not be the best option for quickly growing breast cancer.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "3",
        "PMID": "17530429",
        "title": "Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis",
        "journal": "Breast Cancer Res Treat",
        "abstract": "The randomized multicenter study on rapidly proliferating breast cancer was activated at the end of the 1980s. The present work investigated whether and to what degree the short\u2010term advantages observed from treatment A were maintained at a longer follow\u2010up. Two hundred and eighty\u2010one patients with node\u2010negative and high TLI tumors were randomized to receive treatment A or no further treatment. At a median follow\u2010up of 12 years, treatment A produced a 25% and 20% relative reduction in relapse and death cumulative incidence, respectively. A breakdown analysis identified a subgroup of patients with intermediate proliferating tumors for whom a 70% and 73% reduction in relapse and death was observed in the intention\u2010to\u2010treat population. An even higher reduction of 80% and 84% in relapse and death was seen for the patients who had received the full treatment A dose. We identified a subgroup of patients with intermediate proliferating tumors in whom the high benefit obtained from treatment A was maintained at a long\u2010term follow up.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help!\n\nSo, there was a big study done on cancer treatment. The study looked at how well a certain treatment worked for people with breast cancer. The treatment was given to 281 people with breast cancer that had not spread to other parts of their body.\n\nThe study found that the treatment helped reduce the risk of the cancer coming back by 25% and 20% for some people. That means that out of 100 people, 25 and 20 would not have their cancer come back after treatment.\n\nBut here's the interesting part: the study also found that for some people with intermediate-growing tumors, the treatment worked even better! For these people, the treatment reduced the risk of the cancer coming back by 70% and 73%. That's like 45 out of 100 people not having their cancer come back!\n\nThe study also found that for people who got the full dose of the treatment, the benefit was even higher - 80% and 84% reduction in cancer coming back!\n\nSo, in summary, the study showed that this treatment can be effective in reducing the risk of breast cancer coming back for some people, especially those with intermediate-growing tumors. However, it's important to keep in mind that the study was done on a small"
    },
    {
        "id": "36",
        "PMID": "18794551",
        "title": "Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nThis phase III randomized open\u2010label clinical trial was designed to evaluate the efficacy and safety of treatment A versus comparator B as first\u2010line treatment for metastatic breast cancer (MBC) in postmenopausal women.\nPatients and methods:\nThe study was conducted at 81 centers and enrolled postmenopausal patients with measurable hormone\u2010sensitive metastatic or locally advanced breast cancer. Prior adjuvant chemotherapy and/or comparator B were allowed. One previous chemotherapy regimen and no prior hormone therapy for advanced disease were permitted. Patients were randomly assigned to receive treatment A or comparator B until disease progression or unacceptable toxicity occurred. Progression\u2010free survival (PFS) as the primary study end point.\nResults:\nOf the 382 patients randomized at 79 sites, 371 (182 treatment A, 189 comparator B) were included in the analysis. No treatment related death were observed. A total of 319 events (progression or death) were observed: 161 (85%) in the comparator B arm and 158 (87%) in the treatment A arm. Median progression\u2010 free survival (PFS) (primary outcome) was 5.8 months with comparator B (95% CI, 5.3 to 8.1 months) vs 9.9 months; (95% CI, 8.7 to 11.8 months) with treatment A, HR = 0.84 (95% CI, 0.67 to 1.05), p = .121. No statistically significant differences in overall survival were observed between treatment arms: median overall survival for comparator B and treatment A was 43.3 vs. 37.2 months, HR=1.04 (95% CI, 0.76 to 1.41). Overall response rate was respectively for treatment A and for comparator B, 46% vs. 31%; odds ratio=1.85; 95% CI, 1.21 to 2.82; P = .005.\nConclusion:\nTreatment A was not more effective than comparator B for metastatic breast cancer in postmenopausal women on overall survival.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see which treatment is best for women with breast cancer that has spread to other parts of their body. The study compared two different treatments, called \"Treatment A\" and \"Comparator B.\" The researchers looked at how well each treatment worked in terms of how long the cancer didn't grow or spread, and how long the women lived.\n\nThe results showed that Treatment A didn't do any better than Comparator B in terms of making the cancer go away or helping the women live longer. Both treatments worked about the same. The researchers looked at other things too, like how well the treatments worked for different groups of women, but they found that Treatment A wasn't any better than Comparator B overall.\n\nSo, the study found that Treatment A and Comparator B are about the same in terms of helping women with breast cancer live longer and making the cancer go away. This means that doctors can use either treatment for these women, and they should expect about the same results.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "35",
        "PMID": "18794551",
        "title": "Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nThis phase III randomized open\u2010label clinical trial was designed to evaluate the efficacy and safety of treatment A versus comparator B as first\u2010line treatment for metastatic breast cancer (MBC) in postmenopausal women.\nPatients and methods:\nThe study was conducted at 81 centers and enrolled postmenopausal patients with measurable hormone\u2010sensitive metastatic or locally advanced breast cancer. Prior adjuvant chemotherapy and/or comparator B were allowed. One previous chemotherapy regimen and no prior hormone therapy for advanced disease were permitted. Patients were randomly assigned to receive treatment A or comparator B until disease progression or unacceptable toxicity occurred.\nResults:\nA total of 371 patients enrolled at 79 sites (182 treatment A, 189 comparator B) were included in the analysis. Both treatments were generally well tolerated without major toxicity. Overall response rate was greater for treatment A than for comparator B (46% v 31%; odds ratio = 1.85; 95% CI, 1.21 to 2.82; P = .005). Median progression\u2010free survival (PFS) was longer with treatment A (9.9 months; 95% CI, 8.7 to 11.8 months) than with comparator B (5.8 months; 95% CI, 5.3 to 8.1 months). However, these early differences (Wilcoxon P = .028) did not translate to a longer\u2010term benefit in PFS, the primary study end point (log\u2010rank P = .121). There was also no difference in survival between both study arms.\nConclusion:\nTreatment A is an effective and well\u2010tolerated first\u2010line hormonal treatment for postmenopausal women with MBC and offers significant early improvement in time to tumor progression when compared with comparator B.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see which treatment is best for women with a type of cancer called metastatic breast cancer (MBC). The study compared two different treatments, called \"Treatment A\" and \"Comparator B\". The researchers wanted to see which one worked better and was safer for the women.\n\nThe study found that Treatment A was better than Comparator B in some ways. For example, more women who got Treatment A had their cancer shrink or go away faster than the women who got Comparator B. But the difference wasn't big enough to be considered very important.\n\nThe study also found that Treatment A was generally well-tolerated, which means it didn't cause too many side effects. But Comparator B caused more side effects.\n\nSo, the study suggests that Treatment A might be a good option for women with MBC, but more research is needed to confirm this. It's important to remember that this is just one study, and there are many other factors that can affect the outcome of cancer treatment.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "17",
        "PMID": "18955454",
        "title": "Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nTreatment A is effective against HER\u20102\u2010positive locally advanced or metastatic breast cancer (MBC). This phase III trial evaluated the efficacy of treatment A in HER\u20102\u2010negative and HER\u20102\u2010uncharacterized MBC.\nPatients and methods:\nWomen with MBC were randomly assigned to first\u2010line therapy with paclitaxel 175 mg/m2 every 3 weeks plus treatment A or placebo. A preplanned retrospective evaluation of HER\u20102 status was performed using fluorescence in situ hybridization and immunohistochemistry. The primary end point was time to progression (TTP); secondary end points were objective response rate (ORR), clinical benefit rate (CBR), event\u2010free survival (EFS), and overall survival (OS).\nResults:\nIn the intent\u2010to\u2010treat population (n = 579), there were no significant differences in TTP, EFS, or OS between treatment arms, although differences in ORR and CBR were noted. In 86 HER\u20102\u2010positive patients (15%), treatment with paclitaxel\u2010 treatment A resulted in statistically significant improvements in TTP, EFS, ORR, and CBR compared with paclitaxel\u2010placebo. No differences between treatment groups were observed for any end point in HER\u20102\u2010negative patients. The most common adverse events were alopecia, rash, and diarrhea. The incidence of diarrhea and rash was significantly higher in the paclitaxel\u2010treatment A arm. The rate of cardiac events was low, and no difference was observed between treatment arms.\nConclusion:\nPatients with HER\u20102\u2010negative or HER\u20102\u2010untested MBC did not benefit from the addition of treatment A to paclitaxel. However, first\u2010line therapy with paclitaxel\u2010 treatment A significantly improved clinical outcomes in HER\u20102\u2010positive patients. Prospective evaluation of the efficacy and safety of this combination is ongoing in early and metastatic HER\u20102\u2010positive breast cancer patients.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a new treatment called \"treatment A\" works for people with a type of cancer called breast cancer. The study looked at how well the treatment worked for people who had a certain type of breast cancer that is called \"HER-2 positive.\"\n\nThe study found that for people with HER-2 positive breast cancer, the treatment of paclitaxel (a chemotherapy drug) plus treatment A worked really well and helped them live longer without their cancer getting worse. The treatment also made them feel better and helped them have fewer side effects.\n\nHowever, the study also found that for people with breast cancer that is not HER-2 positive, the addition of treatment A to paclitaxel did not help them as much.\n\nSo, the study showed that treatment A is most helpful for people with HER-2 positive breast cancer, but it may not be as helpful for people with other types of breast cancer. It's important to know which type of breast cancer you have so that you can get the best treatment for you.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "18",
        "PMID": "18955454",
        "title": "Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nThis phase III trial evaluated the efficacy of treatment A in locally advanced or metastatic breast cancer (MBC).\nPatients and methods:\nWomen with MBC were randomly assigned to first\u2010line therapy with paclitaxel 175 mg/m2 every 3 weeks plus treatment A or placebo. The primary end point was time to progression (TTP); secondary end points were objective response rate (ORR), clinical benefit rate (CBR), event\u2010free survival (EFS), and overall survival (OS).\nResults:\nThis trial enrolled 580 patients. In the intent\u2010to\u2010treat population (n = 579), there were no statistical significant differences between treatment A+paclitaxel and placebo+paclitaxel in TTP (29 v 22.9 weeks, HR = 0.87; 95% CI, 0.72 to 1.05; p = .142), EFS (25.1 vs. 22.6 weeks, HR = 0.90 [0.75\u20101.08], p = 0.238), or OS (99.1 vs. 87 weeks, HR = 0.86 [0.7\u20101.1], p = 0.216). The ORR and CBR were respectively for treatment A and placebo 35.1% vs. 25.3%, p = 0.008 and 40.5% vs. 31.9%, p = 0.025. The most common adverse events were alopecia, rash, and diarrhea. The incidence of diarrhea, rash, mucositis, and vomiting was significantly higher in the paclitaxel\u2010treatment A arm. The rate of cardiac events was low, and no statistical difference was observed between treatment arms. AEs led to treatment discontinuation in 48 patients (16%) in the paclitaxel\u2010treatment A arm compared with 20 patients (7%) in the paclitaxel\u2010placebo arm.\nConclusion:\nTreatment A plus paclitaxel was not more effective than paclitaxel alone on overall survival for patients with locally advanced or metastatic breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a new treatment called \"treatment A\" works for people with breast cancer that has spread to other parts of their body (called \"metastatic breast cancer\"). The study looked at how long these patients lived and how well the treatment worked.\n\nThe study found that the new treatment didn't really help these patients live longer than the standard treatment that most doctors use. In fact, the patients who got the new treatment didn't live any longer than the patients who got the standard treatment.\n\nBut, the study did find that the new treatment worked a little better for some patients in certain ways. For example, more patients who got the new treatment had their cancer shrink or go away completely compared to the standard treatment. And, fewer patients who got the new treatment had side effects like nausea or vomiting compared to the standard treatment.\n\nSo, while the new treatment didn't work as well as hoped for all patients, it might be helpful for some patients in certain ways. But, more research is needed to figure out which patients might benefit the most from this treatment.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "15",
        "PMID": "19273714",
        "title": "Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nThis phase III study compared the efficacy and safety of treatment A with comparator B in advanced breast cancer.\nPatients and methods:\nPatients were randomly assigned to treatment A or comparator B. Comparison of progression\u2010free survival (PFS) was the primary objective.\nResults:\nPatient characteristics were balanced between arms (N = 305). Median PFS was 8.05 months (95% CI, 6.60 to 8.71) for treatment A and 7.98 (95% CI, 6.93 to 8.77) for comparator B (log\u2010rank P = .121). Overall response rate (ORR) was 32% in both arms, and overall survival (OS) was not different between arms (P = .983). Time to treatment failure (TTF; defined as discontinuation, progressive disease, death as a result of any cause, or the start of a new anticancer therapy) was superior in the treatment A arm (P = .059). Hematologic toxicity was similar in both arms, except for grades 3 to 4 leukopenia (treatment A, 78%; comparator B, 66%; P = .025) and transfusions (treatment A, 17%; comparator B, 7%; P = .0051). Grades 3 to 4 diarrhea, mucositis, and hand\u2010and\u2010foot syndrome were significantly higher in the comparator B arm. Fewer patients in the treatment A arm discontinued because of drug\u2010related adverse events (13% v 27% in CD; P = .002).\nConclusion:\nNo difference was observed between treatment A and comparator B arms in PFS, ORR, and OS. TTF was longer in the treatment A arm. These findings, combined with a nonhematologic toxicity profile that favors treatment A over approved doses of comparator B, suggest that treatment A may be a better option than comparator B in this clinical setting.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see which treatment is better for people with breast cancer. The study compared two different treatments, called \"Treatment A\" and \"Comparator B.\" The researchers looked at how well the treatments worked and how safe they were.\n\nThey found that the two treatments didn't really differ much in terms of how long the cancer didn't grow (called \"progression-free survival\"). They also found that the treatments didn't differ much in terms of how many patients had a good response to the treatment (called \"overall response rate\"). However, the researchers did find that one treatment had a slightly longer time until the cancer grew again (called \"time to treatment failure\").\n\nThe researchers also looked at how often patients had side effects from the treatments. They found that one treatment had fewer side effects, especially when it came to things like low white blood cell counts and needing blood transfusions.\n\nOverall, the study found that the two treatments were pretty similar, but one of them had a few advantages when it came to side effects. However, the researchers were careful to say that more research is needed to confirm their findings.\n\nSo, in plain language, the study showed that there are"
    },
    {
        "id": "16",
        "PMID": "19273714",
        "title": "Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nThis phase III study compared the efficacy and safety of treatment A with comparator B in advanced breast cancer.\nPatients and methods:\nPatients were randomly assigned to treatment A or comparator B. Comparison of progression\u2010free survival (PFS) was the primary objective.\nResults:\nPatient characteristics were balanced between arms (N = 305). Median PFS was 8.05 months (95% CI, 6.60 to 8.71) for treatment A and 7.98 (95% CI, 6.93 to 8.77) for comparator B (log\u2010rank P = .121). Overall response rate (ORR) was 32% in both arms, p=0.931. The median time to treatment failure (TTF; defined as discontinuation, progressive disease, death as a result of any cause, or the start of a new anticancer therapy) was 4.24 months (95% CI, 4.11 to 4.44) for treatment A and 4.07 months (95% CI, 3.81 to 4.24) for comparator B, p=0.059. The medial overall survival was 19.29 months (95% CI, 15.57 to 23.59) for treatment A vs. 21.45 months (95% CI, 17.12 to 24.94), p=0.983. Hematologic toxicity was similar in both arms, except for grades 3 to 4 leukopenia (treatment A, 78%; comparator B, 66%; P = .025) and transfusions (treatment A, 17%; comparator B, 7%; P = .0051) and grades 3 to 4 diarrhea (treatment A, 8%; comparator B, 18%; p=0.009), mucositis (treatment A, 4%; comparator B, 15%; p<.001), and hand\u2010and\u2010foot syndrome (treatment A, 0%; comparator B, 26%, p<.001). 13% in treatment A arm and 27% in the comparator B arm discontinued because of drug\u2010related adverse events (P = .002).\nConclusion:\nTreatment A was not more effective than comparator B for patients with advanced breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see which treatment is better for people with breast cancer. The study compared two different treatments, called \"Treatment A\" and \"Comparator B.\" The researchers looked at how well the treatments worked and how safe they were.\n\nThey found that the two treatments were about the same in terms of how well they worked. Both treatments helped keep the cancer from growing for a while, but there was no big difference between them. They also found that the treatments were about the same in terms of how safe they were, except that some people in the Treatment A group had more side effects like feeling tired or having diarrhea.\n\nSo, the study found that Treatment A and Comparator B are about the same for treating breast cancer. The researchers think that Treatment A might be a good option, but they want to do more studies to make sure it's the best treatment.\n\nIt's important to remember that this is just one study, and there are many other studies that need to be done to confirm the results. But overall, the study found that Treatment A and Comparator B are about the same for treating breast cancer."
    },
    {
        "id": "42",
        "PMID": "20087643",
        "title": "A bupropion smoking cessation clinical trial for cancer patients",
        "journal": "Cancer Causes Control",
        "abstract": "Objective:\nMany cancer patients continue to smoke postdiagnosis, yet there have been few smoking cessation trials for this population.\nMethods:\nThis double\u2010blind placebo\u2010controlled trial randomized 246 cancer patients to 9 weeks of placebo or treatment A, stratifying by pre\u2010treatment depression symptoms. In addition, all patients received transdermal nicotine and behavioral counseling. Primary outcomes were 7\u2010day point\u2010prevalence abstinence, biochemically confirmed, at the end of treatment (Week 12), and at 6 months post quit day (Week 27). Additional outcomes included: withdrawal, affect, quality of life, compliance, and side effects.\nResults:\nThere was no main effect of treatment A vs. placebo on abstinence (Odds Ratio [OR] = 1.36, 95% CI: 0.38\u20104.81, p =0.64). At week 12, the abstinence rates were 24.2% for placebo and 27.2% for treatment A; at week 27, the abstinence rates were 17.4% for placebo and 18.4% for treatment A. There was no statistically significant difference between placebo and treatment A in average daily smoking to week 12 (mean [SE] 5.2 [0.95] vs. 5.3 [1.0]; p=0.97); and to week 27 (mean [SE] 5.4 [0.88] vs. 6.1 [0.90]; p=0.64). There were no statistically significant difference between placebo and treatment A on changes in withdrawals (p=0.39); negative (p=0.41) and positive affect (p=0.77), and physical (p=0.31) and mental (p=0.42) quality of life.\nConclusion:\nTreatment A was not more effective than placebo on the prevalence of abstinence of cancer patients who continue to smoke postdiagnosis.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done with cancer patients who were still smoking after they got sick. The study wanted to see if a special treatment could help them stop smoking. The treatment was either a placebo (which means a fake medicine) or a real medicine. The study found out that the treatment didn't work very well. Only a little bit of the patients were able to stop smoking after taking the medicine.\n\nThe study also looked at how the patients felt and how their quality of life was before and after taking the medicine. It found that the medicine didn't make a big difference in how the patients felt or how their quality of life was.\n\nSo, the study concluded that the medicine wasn't very effective in helping cancer patients stop smoking. But, the study also said that it's important to keep trying to find ways to help cancer patients stop smoking, because it's not good for their health.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "41",
        "PMID": "20087643",
        "title": "A bupropion smoking cessation clinical trial for cancer patients",
        "journal": "Cancer Causes Control",
        "abstract": "Objective:\nMany cancer patients continue to smoke postdiagnosis, yet there have been few smoking cessation trials for this population. Depression, which is prevalent among cancer patients, may be a barrier to cessation.\nMethods:\nThis double\u2010blind placebo\u2010controlled trial randomized 246 cancer patients to 9 weeks of placebo or treatment A, stratifying by pre\u2010treatment depression symptoms. In addition, all patients received transdermal nicotine and behavioral counseling. Primary outcomes were 7\u2010day point\u2010prevalence abstinence, biochemically confirmed, at the end of treatment (Week 12), and at 6 months post quit day (Week 27). Additional outcomes included: withdrawal, affect, quality of life, compliance, and side effects.\nResults:\nThere was no main effect of treatment A vs. placebo on abstinence (Odds Ratio [OR] = 1.36, 95% CI: 0.38\u20104.81, p = 0.64). Patients with depression symptoms reported significantly lower abstinence rates vs. patients without depression symptoms (OR = .14, 95% CI: 0.02\u20100.80, p=0.03). Treatment A increased abstinence rates, vs. placebo, more for participants with depression vs. those without depression symptoms. For patients with depression symptoms, treatment A reduced withdrawal symptoms and improved quality of life vs. placebo.\nConclusion:\nFor patients with depression symptoms, treatment increases abstinence rates, lowers withdrawal, and increases quality of life. However, abstinence rates among patients with depression symptoms were low vs. patients without depression symptoms, who exhibited similar abstinence rates when treated with treatment A or transdermal nicotine and counseling alone. These results can guide future smoking cessation intervention studies with cancer patients.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help!\n\nSo, there was a big study done with cancer patients who smoke. The study wanted to see if a special treatment could help them stop smoking. The treatment was either a placebo (which means a fake medicine) or a real medicine called \"treatment A.\" The study found out that the treatment didn't really help the patients stop smoking overall, but it did help some of the patients who had feelings of sadness or depression. These patients had better results with the treatment than the patients who didn't have depression.\n\nThe study also found that the treatment helped some of the patients feel less sick and have a better quality of life. But, even though the treatment didn't work for most of the patients, it's important to keep trying to find ways to help people stop smoking, especially if they have depression.\n\nSo, the study showed that the treatment might be helpful for some cancer patients with depression, but it's not a magic solution that works for everyone. It's important to keep researching and trying new things to help people stop smoking.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "21",
        "PMID": "20153039",
        "title": "Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial",
        "journal": "Lancet",
        "abstract": "Background:\nWe aimed to compare overall survival in patients receiving treatment A or comparator B.\nMethods:\nThis was an open\u2010label randomized trial undertaken in 50 centres across eight countries. 1006 treatment\u2010naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated (1 to 1) by minimization to receive comparator B or treatment A. Treatment was not masked. The primary endpoint was overall survival. Treatment groups were compared with a non\u2010stratified log\u2010 rank test. Analysis was by intention to treat. This study is registered, number ISRCTN XXXX.\nFindings:\n502 patients were randomly assigned to receive comparator B and 504 to receive combined treatment A. Median follow\u2010up was 37.2 months (24.8\u201052.3). Median overall survival was 18.8 months (17.0\u201023.2) for patients receiving comparator B versus 18.6 months (16.5\u201020.6) for those receiving treatment A. Overall survival did not differ between the two groups (hazard ratio 1.05 [95% CI 0.90\u20101.21], p=0.55; absolute difference 0.3% (\u20105.1 to 5.6) at 1 year and 2.7% (\u20108.2 to 2.9) at 3 years). Serious adverse events were reported in 113 (23%) patients receiving comparator B and 131 (26%) of those receiving combined treatment A.\nInterpretation:\nAlthough treatment A does not improve overall or progression\u2010free survival compared with comparator B, treatment A might still have a role because it can produce remissions that are of clinically relevant length in some patients. Identification of patients who will benefit from treatment A is crucial.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to compare two different treatments for cancer. The study looked at how well the treatments worked and how long the patients lived. The study found that one of the treatments, called \"treatment A,\" didn't really help the patients live any longer than the other treatment, called \"comparator B.\"\n\nBut here's the thing: just because treatment A didn't help the patients live longer, it doesn't mean it's not a good treatment. Sometimes, treatment A can make the cancer go away for a while, even if it's not as long as the other treatment. So, it's important to figure out which patients are most likely to benefit from treatment A.\n\nThe study found that there were some patients who did really well on treatment A, and they lived longer than they would have if they had gotten the other treatment. But there were also some patients who didn't do as well on treatment A, and they lived shorter lives.\n\nSo, the study showed that treatment A can be a good treatment for some patients, but it's important to figure out who those patients are. And the study also showed that it's important to be honest and not try to make the results sound better than they really are.\n"
    },
    {
        "id": "22",
        "PMID": "20153039",
        "title": "Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial",
        "journal": "Lancet",
        "abstract": "Background:\nWe aimed to compare overall survival in patients receiving treatment A or comparator B.\nMethods:\nThis was an open\u2010label randomized trial undertaken in 50 centres across eight countries. 1006 treatment\u2010naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated (1 to 1) by minimization to receive comparator B or treatment A. Treatment was not masked. The primary endpoint was overall survival. Treatment groups were compared with a non\u2010stratified log\u2010 rank test. Analysis was by intention to treat. This study is registered, number ISRCTN XXXX.\nFindings:\n502 patients were randomly assigned to receive comparator B and 504 to receive combined treatment A. Median follow\u2010up was 37.2 months (24.8\u201052.3). Median overall survival was 18.8 months (17.0\u201023.2) for patients receiving comparator B versus 18.6 months (16.5\u201020.6) for those receiving treatment A. Overall survival did not differ between the two groups (hazard ratio 1.05 [95% CI 0.90\u20101.21], p=0.55; absolute difference 0.3% (\u20105.1 to 5.6) at 1 year and 2.7% (\u20108.2 to 2.9) at 3 years). There was no evidence that progression free survival differed statistically between treatment groups (HR 1.02 [0.89\u20131.16]; p=0.81). During treatment significantly more grade 3 and 4 toxic effects were associated with combined treatment A than with comparator B (269 patients [53%] vs. 183 patients [36%]; p<0.0001). Serious adverse events were reported in 113 (23%) patients receiving comparator B and 131 (26%) of those receiving combined treatment A.\nInterpretation:\nTreatment A was not more effective than comparator B on overall survival in patients diagnosed with advanced metastatic renal cell carcinoma.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see which treatment is better for people with a type of cancer called renal cell carcinoma. The study compared two different treatments, called \"treatment A\" and \"comparator B.\" The researchers wanted to see if one of these treatments helped people live longer.\n\nThey looked at 1006 patients who had this type of cancer and were not yet sick enough to need hospice care. They divided these patients into two groups and gave one group treatment A and the other group comparator B. They made sure that the groups were similar in terms of age, gender, and other things that could affect how well the treatment works.\n\nThe researchers found out that the two groups did not differ much in terms of how long they lived. The median time until they died was 18.8 months for the group that got treatment A and 18.6 months for the group that got comparator B. This means that the two treatments were not much different in terms of how well they worked.\n\nHowever, the researchers did find that the group that got treatment A had more side effects than the group that got comparator B. Side effects are things that happen to your body when you take a medicine, like feeling sick or having a"
    },
    {
        "id": "59",
        "PMID": "20448107",
        "title": "Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma",
        "journal": "Blood",
        "abstract": "In this double\u2010blind, placebo\u2010controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan\u2010prednisone and treatment A or melphalan\u2010prednisone and placebo. The dose of melphalan was 0.25 mg/kg and prednisone was 100 mg given daily for 4 days every 6 weeks until plateau phase. A total of 357 patients were analyzed. Partial response was 34% and 33%, and very good partial response or better was 23% and 7% in the treatment A and placebo arms, respectively (P < .001). There was no significant difference in progression\u2010free or overall survival, with median survival being 29 months in the treatment A arm and 32 months in the placebo arm. Most quality of life outcomes improved equally in both arms, apart from constipation, which was markedly increased in the treatment A arm. Constipation, neuropathy, non\u2010neuropathy neurologic toxicity, and skin reactions were significantly more frequent in the treatment A arm. The number of thromboembolic events was equal in the 2 treatment arms. In conclusion, treatment A had a significant antimyeloma effect, but this did not translate into improved survival.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help!\n\nSo, there was a big study done to test a new treatment for people with a type of cancer called multiple myeloma. The study involved 363 people who didn't have any treatment for their cancer yet. They were divided into two groups: one group got a treatment called melphalan-prednisone and the other group got a pretend treatment (called a placebo) with the same doses of melphalan and prednisone.\n\nThe study found that the treatment group had a better response to the cancer, with 34% of them showing a partial response and 23% showing a very good partial response or better. However, the study also found that the treatment didn't really improve the survival rate of the patients. The median survival time was 29 months for the treatment group and 32 months for the placebo group.\n\nThe study also looked at how the treatment affected the patients' quality of life. It found that some side effects, like constipation, were more common in the treatment group, but most of the other quality of life measures were the same in both groups.\n\nOverall, the study suggests that the treatment may be effective in treating multiple myeloma, but it didn't really improve the survival rate of the patients. However, the study also found some side effects that were more"
    },
    {
        "id": "60",
        "PMID": "20448107",
        "title": "Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma",
        "journal": "Blood",
        "abstract": "In this double\u2010blind, placebo\u2010controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan\u2010prednisone and treatment A or melphalan\u2010prednisone and placebo. The dose of melphalan was 0.25 mg/kg and prednisone was 100 mg given daily for 4 days every 6 weeks until plateau phase. The primary outcome was overall survival. A total of 357 patients were analyzed. The median survival was 29 months (95% [CI], 25\u201038 months) in the treatment A arm and 32 months (95% [CI], 27\u201038 months) in the placebo arm; p=0.35. There was no statistically significant difference in progression free survival between the 2 arms with medians of 15 months 95% CI [12\u201019] for the treatment A arm and 14 months 95% CI [11\u201018] for the placebo arm. Partial response was 34% and 33%, and very good partial response or better was 23% and 7% in the treatment A and placebo arms, respectively (P < .001). Constipation, neuropathy, non\u2010neuropathy neurologic toxicity, and skin reactions were significantly more frequent in the treatment A arm. The number of thromboembolic events was 8% in both arms. In conclusion, treatment A was not more effective than placebo on overall survival in patients with multiple myeloma.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, in this study, researchers looked at a new treatment for people with a type of cancer called multiple myeloma. They divided the patients into two groups and gave one group the new treatment, while the other group got a pretend treatment (called a \"placebo\"). They then looked at how well the treatments worked and what side effects the patients had.\n\nThe results showed that the two groups didn't differ much in terms of how long they lived (called \"overall survival\"). The median survival time was 29 months for one group and 32 months for the other, which isn't a big difference. They also looked at how well the treatments worked in terms of keeping the cancer from growing (called \"progression-free survival\"), and found that the two groups didn't differ much there either.\n\nHowever, the researchers did find some differences between the two groups in terms of side effects. Some patients in the treatment group had more problems with constipation, nerve damage, and skin reactions, while others in the placebo group had more problems with nerve damage.\n\nOverall, the study found that the new treatment didn't seem to be much more effective than the pretend treatment in terms of overall survival or keeping the cancer from"
    },
    {
        "id": "50",
        "PMID": "20530276",
        "title": "Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nWe sought to determine whether treatment A improved overall survival (OS) compared with comparator B in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes.\nPatients and methods:\nA total of 1,221 patients with MBC previously treated with anthracycline and taxanes were randomly assigned to treatment A or comparator B (2,500 mg/m2 on the same schedule) given every 21 days. The trial was powered to detect a 20% reduction in the hazard ratio (HR) for death.\nResults:\nThere was no significant difference in OS between the treatment A and comparator B arm, the primary end point (median, 16.4 v 15.6 months; HR = 0.9; 95% CI, 078 to 1.03; P = .1162). The arms were well balanced with the exception of a higher prevalence of impaired performance status (Karnofsky performance status 70% to 80%) in the treatment A arm (32% v 25%). Grade 3 to 4 neuropathy occurred in 24% treated with the treatment A compared to 1.2% treated with comparator B. The median time to improvement of grade 3 or worse treatment related neuropathy by at least one grade was 4.5 weeks. Grade 3\u20104 neutropenia and grade 3\u20104 febrile neutropenia occurred in 73% and 7% treated with the treatment A versus 9% and 0.6% treated with comparator B. Grade 3\u20104 fatigue occurred in 12% treated with the treatment A versus 3% treated with comparator B.\nConclusion:\nThe treatment A was not more effective than comparator B on overall survival in patients with metastatic breast cancer previously treated with anthracycline and taxanes.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if one treatment worked better than another for people with a type of cancer called metastatic breast cancer. The treatment was given to 1,221 people who had already been treated with other medicines called anthracyclines and taxanes. The study found out that the two treatments were not very different in terms of how long the patients lived.\n\nThe study looked at some other things too, like how many patients had side effects from the treatments. It found that some patients who got the first treatment had more nerve problems and felt more tired than the patients who got the other treatment. But overall, the two treatments were pretty similar.\n\nThe study's conclusion was that the first treatment was not much better than the other treatment for these patients. So, doctors might want to try other treatments for these patients instead.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "49",
        "PMID": "20530276",
        "title": "Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nWe sought to determine whether treatment A improved overall survival (OS) compared with comparator B in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes.\nPatients and methods:\nA total of 1,221 patients with MBC previously treated with anthracycline and taxanes were randomly assigned to treatment A or comparator B (2,500 mg/m2 on the same schedule) given every 21 days. The trial was powered to detect a 20% reduction in the hazard ratio (HR) for death.\nResults:\nThere was no significant difference in OS between the treatment A and comparator B arm, the primary end point (median, 16.4 v 15.6 months; HR = 0.9; 95% CI, 078 to 1.03; P = .1162). The arms were well balanced with the exception of a higher prevalence of impaired performance status (Karnofsky performance status 70% to 80%) in the treatment A arm (32% v 25%). In a secondary Cox regression analysis adjusted for performance status and other prognostic factors, OS was improved for the treatment A (HR = 0.85; 95% CI, 0.75 to 0.98; P = .0231). In 79% of patients with measurable disease, the treatment A significantly improved progression\u2010free survival (PFS; median, 6.2 v 4.2 months; HR = 0.79; P = .0005) and response rate (43% v 29%; P < .0001). Grade 3 to 4 neuropathy occurred in 24% treated with the treatment A combination, but was reversible.\nConclusion:\nThis study confirmed a previous trial demonstrating improved PFS and response for the treatment A compared with comparator B alone, although this did not result in improved survival.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a new treatment for cancer works better than another treatment that doctors already use. The study looked at 1,221 people with cancer that had spread to other parts of their body. Half of these people got the new treatment, and the other half got a different treatment.\n\nThe study found that the new treatment didn't make a big difference in how long these people lived. Both groups of patients lived about the same amount of time, which was around 16 months. But, the new treatment did help some patients live longer if they had measurable cancer.\n\nThe study also found that some patients who got the new treatment had a higher chance of having side effects, like feeling very tired or having numbness in their hands and feet. But, these side effects went away on their own.\n\nSo, the study showed that the new treatment might be helpful for some patients with cancer, but it's not a cure-all. Doctors will still need to use other treatments to help patients with cancer live longer and feel better.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "24",
        "PMID": "20564068",
        "title": "A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study",
        "journal": "Cancer",
        "abstract": "Background:\nCancer\u2010related fatigue is a debilitating symptom affecting psychosocial functioning and quality of life in 70% to 100% of cancer patients during and after treatment. The authors examined the effect of 200 mg of treatment A compared to placebo on the severity of cancer\u2010related fatigue.\nMethods:\nThe authors conducted a multicenter, randomized, double\u2010blind, placebo\u2010 controlled, phase 3, clinical trial to examine the effect of treatment A on patient\u2010 reported fatigue in cancer patients undergoing chemotherapy. A sample of 877 cancer patients beginning chemotherapy at 23 geographically separate University of Rochester Cancer Center (URCC) Community Clinical Oncology Program (CCOP) affiliates were assessed for fatigue. Patients who reported fatigue (N = 867) were randomly assigned to receive either treatment A or a placebo. Treatment began on Day 5 of Cycle 2 and ended after Day 7 of Cycle 4. Fatigue, sleepiness and depression were assessed during Cycles 2 to 4 by using psychometrically valid measures. The primary outcome was the worst level of cancer related fatigue during the previous week at Cycle 4. Group differences (treatment vs. placebo) were examined by using an analysis of covariance (ANCOVA) adjusting for baseline fatigue (Cycle 2).\nResults:\nThere were 631 patients (315 treatment A, 316 placebo) who provided evaluable data and were analyzed. There was no statistical significant difference for the worst level of cancer related fatigue between treatment A (mean (SE) = 6.87 (0.14) and placebo (mean (SE) = 7.09 (0.13); p = 0.08. Sleepiness was statistically significantly higher in placebo (mean (SE) = 18.38 (0.31) vs. treatment A (mean (SE) = 16.82 (0.26); p = 0.002. Treatment A had no statistically significant effect on depression (p=0.87)\nConclusion:\nTreatment A was not more effective than placebo in controlling cancer\u2010related fatigue.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a special treatment could help people who are feeling really tired because they have cancer. The treatment was given to a bunch of people who were starting chemotherapy, and the researchers wanted to see if it made their fatigue better. They looked at how tired the patients were during the first four days of chemotherapy, and they found out that the treatment didn't really make a difference in how tired they felt.\n\nBut, the researchers did find out that the patients who got the treatment were a little bit more sleepy than the ones who didn't get the treatment. They also looked at whether the treatment helped with feelings of depression, and they found out that it didn't make a difference there either.\n\nSo, the study didn't show that the treatment helped with cancer-related fatigue, but it did show that the patients who got the treatment were a bit more sleepy. It's important to remember that this study was done with a small group of people, and more research needs to be done to see if the treatment is effective for everyone."
    },
    {
        "id": "23",
        "PMID": "20564068",
        "title": "A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study",
        "journal": "Cancer",
        "abstract": "Background:\nCancer\u2010related fatigue is a debilitating symptom affecting psychosocial functioning and quality of life in 70% to 100% of cancer patients during and after treatment. The authors examined the effect of treatment A on the severity of cancer\u2010related fatigue.\nMethods:\nThe authors conducted a multicenter, randomized, double\u2010blind, placebo\u2010 controlled, phase 3, clinical trial to examine the effect of treatment A on patient\u2010 reported fatigue in cancer patients undergoing chemotherapy. A sample of 877 cancer patients beginning chemotherapy at 23 geographically separate University of Rochester Cancer Center (URCC) Community Clinical Oncology Program (CCOP) affiliates were assessed for fatigue. Patients who reported fatigue (N = 867) were randomly assigned to receive either treatment A or a placebo. Treatment began on Day 5 of Cycle 2 and ended after Day 7 of Cycle 4. Fatigue and depression were assessed during Cycles 2 to 4 by using psychometrically valid measures. Group differences (treatment vs. control) in the worst level of fatigue during the previous week at Cycle 4 were examined by using an analysis of covariance (ANCOVA) adjusting for baseline fatigue (Cycle 2).\nResults:\nThere were 631 patients (315 treatment A, 316 placebo) who provided evaluable data. ANCOVA showed a significant interaction between treatment condition and baseline fatigue (P = .017), where patients with severe baseline fatigue (n = 458) benefited from treatment A, whereas patients with mild or moderate fatigue did not. Treatment A had no statistically significant effect on depression (P > .05).\nConclusions:\nTreatment A may be useful in controlling cancer\u2010related fatigue in patients who present with severe fatigue but is not useful in patients with mild or moderate fatigue.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a special treatment could help people who have cancer feel less tired. The treatment was given to some people, and not given to others. The people who got the treatment were the ones who were very tired at the beginning of the study. The study found that the treatment helped the very tired people feel less tired, but it didn't help the people who weren't as tired.\n\nThe study also looked at whether the treatment helped people feel less sad or depressed, but it didn't find any effect on that. The researchers think that the treatment might be helpful for people who are very tired when they start treatment, but it's not helpful for people who are only a little tired.\n\nIt's important to remember that this study was done on a small group of people, and more research needs to be done to confirm these findings. But overall, the study suggests that this treatment might be useful for some people with cancer who are very tired."
    },
    {
        "id": "10",
        "PMID": "20673585",
        "title": "Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial",
        "journal": "Leuk Res",
        "abstract": "This prospective multicenter phase III clinical trial was designed to assess efficacy and safety of treatment A as an adjunct to de novo AML remission induction therapy (www.clinicaltrials.gov. NCTXXXXX). The primary outcomes were response to induction and overall survival (OS) at 3 years. The characteristics of the 260 patients randomized to cytarabine and idarubicine with treatment A or cytarabine and idarubicine alone (control arm) were similar in both arms. 62.5% of patients randomized in the treatment A arm had a complete response to induction vs. 64.6% in the control arm; p=0.72. The three\u2010year OS rates were not statistically significantly different between treatment A and control arm (25.6 +/\u2010 5.1% vs. 31.8 +/\u2010 5.6%; p=0.38. Treatment A as an adjunct to cytarabine and idarubicine was not more effective than cytarabine and idarubicine alone in acute myeloid leukemia patients.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help!\n\nSo, there was a big study done to see if a new treatment called \"Treatment A\" could help people with a type of cancer called acute myeloid leukemia (AML). The study was done at many hospitals and was called a \"phase III clinical trial.\"\n\nThe researchers looked at how well the treatment worked by seeing how many patients were able to go into remission after receiving the treatment. They also looked at how long the patients were alive three years after starting treatment.\n\nThe results showed that the treatment was not more effective than the standard treatment that doctors already use. In other words, the treatment did not help the patients live longer or get better faster.\n\nThe study found that 62.5% of patients who received the new treatment had a complete response to induction, which means they went into remission. This is similar to the percentage of patients who received the standard treatment and had a complete response (64.6%).\n\nThe study also found that the three-year survival rates were not significantly different between the two groups. In other words, the patients who received the new treatment did not live longer than the patients who received the standard treatment.\n\nSo, in summary, the study did not find that the new treatment was more effective than the standard treatment for acute myeloid leukemia. The results"
    },
    {
        "id": "9",
        "PMID": "20673585",
        "title": "Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trial",
        "journal": "Leuk Res",
        "abstract": "This prospective multicenter phase III clinical trial was designed to assess efficacy and safety of treatment A as an adjunct to de novo AML remission induction therapy (www.clinicaltrials.gov. NCTXXXXX). Patients' characteristics were similar in both arms. Treatment A improved severity and duration of leukopenia. Three\u2010 year OS were similar (25.6 +/\u2010 5.1% vs. 31.8 +/\u2010 5.6%) in both arms except for patients with myeloblastic features. Significant factors for better survival were the use of treatment A (p = 0.049), female sex (p = 0.05) and single induction cycle (p < 0.001) in multivariate analysis. Female patients performed better than male patients. Better survival obtained among female AML patients needs to be validated within the context of cytogenetic analysis.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a new treatment works for people with a type of cancer called acute myeloid leukemia (AML). The study was done at many hospitals and was called a \"phase III clinical trial.\" The researchers wanted to know if the new treatment helps people with AML get better and live longer.\n\nThe study found that the new treatment helped some people with AML feel better faster and stay in remission longer. But, the study also found that some people with AML who had certain special features in their cancer did not do as well with the new treatment.\n\nThe researchers also looked at some other things that might affect how well people with AML do, like if they were male or female, or if they had only one round of treatment. They found that female patients tended to do better than male patients, and that patients who had only one round of treatment did better than those who had more rounds.\n\nOverall, the study suggests that the new treatment might be helpful for some people with AML, but more research is needed to confirm these findings and to see if the treatment works for everyone with AML.\n\nSo, the abstract is telling us that there is a new treatment for AML that might help some people"
    },
    {
        "id": "30",
        "PMID": "20800381",
        "title": "Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4",
        "journal": "Int J Radiat Oncol Biol Phys",
        "abstract": "Purpose:\nA two\u2010arm, double\u2010blind, randomized trial was performed to evaluate the effect of treatment A on acute skin\u2010related toxicity in patients undergoing breast or chest wall radiotherapy.\nMethods and material:\nPatients with ductal carcinoma in situ or invasive breast carcinoma who were undergoing external beam radiotherapy to the breast or chest wall were randomly assigned to apply treatment A or placebo cream daily. The primary study endpoint was the provider assessed maximal grade of Common Terminology Criteria for Adverse Events, version 3.0, radiation dermatitis.\nResults:\nA total of 176 patients were enrolled between September 21, 2007, and December 7, 2007. The provider assessed primary endpoint showed no difference in the mean maximum grade of radiation dermatitis by treatment arm (1.2+/\u20100.85 for treatment A vs. 1.3+/\u20100.80 for placebo; p = .18). Severe radiation dermatitis concerned 4 (5%) in both arms; p=.97. The worst grade of any type of toxicity were respectively in the placebo and treatment A groups 9% vs. 2% for grade 3 or 4: 24% vs. 30% for grade 2; 61% vs. 40% for grade 1; and 6% vs. 27% for grade 0; p = .04. For the patient\u2010reported outcome, the maximum Skindex\u201016 score for the treatment A group did not differ between the MMF arm (mean = 1.4) vs. placebo arm (mean = 1.7); p=0.07. The mean score for overall quality of life was 8.3 for treatment A vs. 8.4 for placebo; P> .05. The maximal Skin Toxicity Assessment Tool score was respectively in the treatment A and placebo group 1.5 vs. 2.1 for discomfort or burning (p=.02); 1.5 vs. 2.2 for itching (p = .002), 1.0 vs. 1.4 for pulling (p=.07) and 2.1 vs. 2.5 for discomfort or tenderness (p=.11).\nConclusion:\nTreatment A during radiotherapy was not more effective than placebo on acute skin related toxicity in patients undergoing breast or chest wall radiotherapy.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study where scientists tested a new treatment for people who were getting radiation therapy for cancer. They wanted to see if the new treatment would help reduce the risk of skin problems during radiation therapy.\n\nThe study involved 176 people who were getting radiation therapy for breast or chest wall cancer. Half of them were given the new treatment, called \"Treatment A,\" and the other half were given a placebo (which means they didn't get the real treatment).\n\nThe scientists looked at how many people in each group got skin problems during radiation therapy, and they found that there was no difference between the two groups. Both groups had about the same number of skin problems, including itching, burning, and discomfort.\n\nThe scientists also asked the patients to fill out a survey about their quality of life during the study, and they found that the patients in both groups reported similar levels of quality of life.\n\nOverall, the study found that the new treatment did not seem to help reduce the risk of skin problems during radiation therapy for breast or chest wall cancer.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "29",
        "PMID": "20800381",
        "title": "Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4",
        "journal": "Int J Radiat Oncol Biol Phys",
        "abstract": "Purpose:\nA two\u2010arm, double\u2010blind, randomized trial was performed to evaluate the effect of treatment A on acute skin\u2010related toxicity in patients undergoing breast or chest wall radiotherapy.\nMethods and materials:\nPatients with ductal carcinoma in situ or invasive breast carcinoma who were undergoing external beam radiotherapy to the breast or chest wall were randomly assigned to apply treatment A or placebo cream daily. The primary study endpoint was the provider assessed maximal grade of Common Terminology Criteria for Adverse Events, version 3.0, radiation dermatitis. The secondary endpoints included provider\u2010assessed Common Terminology Criteria for Adverse Events Grade 3 or greater radiation dermatitis and adverse event monitoring. The patient\u2010reported outcome measures included the Skindex\u201016, the Skin Toxicity Assessment Tool, a Symptom Experience Diary, and a quality\u2010of\u2010 life self\u2010assessment. An assessment was performed at baseline, weekly during radiotherapy, and for 2 weeks after radiotherapy.\nResults:\nA total of 176 patients were enrolled between September 21, 2007, and December 7, 2007. The provider assessed primary endpoint showed no difference in the mean maximum grade of radiation dermatitis by treatment arm (1.2 for treatment A vs. 1.3 for placebo; p = .18). Common Terminology Criteria for Adverse Events toxicity was greater in the placebo group (p = .04), primarily from pruritus. For the patient\u2010reported outcome measures, the maximum Skindex\u201016 score for the treatment A group showed less itching (p = .008), less irritation (p = .01), less symptom persistence or recurrence (p = .02), and less annoyance with skin problems (p = .04). The group\u2019s maximal Skin Toxicity Assessment Tool score showed less burning sensation (p = .02) and less itching (p = .002).\nConclusion:\nPatients receiving daily treatment A during radiotherapy might experience reduced acute skin toxicity compared with patients receiving placebo.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help!\n\nSo, there was a big study done to see if a special cream could help people who were getting radiation therapy for cancer. The cream was called \"treatment A\" and it was compared to a placebo cream (which means it didn't really do anything). The study found that the people who used the treatment A cream had less skin problems compared to the people who used the placebo cream.\n\nThe study looked at how much the skin problems bothered the patients and how often they happened. The results showed that the patients who used treatment A had less itching, less irritation, and less annoyance with their skin problems compared to the placebo group.\n\nHowever, the study also found that the patients who used the placebo cream had more skin problems overall compared to the treatment A group. This means that the treatment A cream might be helpful in reducing acute skin toxicity (or side effects) for people getting radiation therapy.\n\nIt's important to note that this study was done in a lab and the results might not be the same for everyone. More research is needed to confirm these findings and to see if the treatment A cream is safe and effective for everyone.\n\nSo, in summary, the study found that a special cream called treatment A might help reduce skin problems for people getting radiation ther"
    },
    {
        "id": "55",
        "PMID": "20973267",
        "title": "Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer",
        "journal": "Int J Gynecol Cancer",
        "abstract": "Objective:\nTo evaluate the safety and efficacy of treatment A in combination with pegylated liposomal doxorubicin (PLD) in platinum\u2010resistant ovarian cancer (OC).\nMethods:\nPatients with platinum\u2010refractory or \u2010resistant primary or secondary) OC were randomized to receive treatment A and PLD at 50 mg/m2 intravenously or PLD alone at 50 mg/m2 intravenously on day 1 every 28 days until tumor progression or unacceptable toxicity. The primary end point was progression\u2010free survival (PFS). Other end points were objective response rate and safety. The study was originally planned for 244 patients. The trial was temporarily placed on hold after 125 patients were randomized while the results of another trial were being reviewed and the sponsor decided not to resume enrollment. The interim analysis became the final analysis.\nResults:\nThe median PFS was 5.6 months for treatment A + PLD (n = 65) versus 3.7 months for PLD (n = 60) (hazards ratio, 0.92; P = 0.7243). A preplanned subgroup analysis showed that 75 patients with platinum\u2010refractory or primary platinum\u2010resistant OC had a median PFS of 5.6 months for treatment A + PLD versus 2.9 months for PLD (hazards ratio, 0.55; P = 0.0425). Hematologic adverse events were 66% on the treatment A + PLD arm versus 44% on the PLD arm, manageable with dose reductions. Nonhematologic adverse events were similar for both arms. The incidence of palmar\u2010plantar erythrodysesthesia and stomatitis was lower on treatment A + PLD (23%, 31%, respectively) versus (39%, 49%, respectively) on PLD.\nConclusion:\nOverall median PFS showed a positive trend but was not statistically significant. The median PFS in the platinum\u2010refractory and primary platinum\u2010resistant OC patients was significantly longer for treatment A + PLD versus PLD. Treatment A may ameliorate the palmar\u2010plantar erythrodysesthesia and stomatitis known to be associated with PLD. Further study of this active well\u2010tolerated regimen in platinum\u2010refractory and primary platinum\u2010resistant OC is planned. This study was registered at www.clinicaltrials.gov",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help!\n\nThe study you mentioned is looking at a new treatment for ovarian cancer. The treatment is called \"treatment A\" and it's being combined with a different drug called \"pegylated liposomal doxorubicin\" (PLD). The researchers want to see if this combination is safe and effective in treating ovarian cancer that has come back after being treated with other drugs.\n\nThe study involved 244 patients who were randomly assigned to receive either treatment A and PLD or just PLD on its own. The researchers looked at how long the patients' cancer stayed under control and how many patients had side effects from the treatment.\n\nThe results showed that the combination of treatment A and PLD didn't significantly prolong the time before the cancer came back (called \"progression-free survival\"). However, the researchers did find that the combination seemed to be more effective in a group of patients who had ovarian cancer that was resistant to other treatments.\n\nThe study also found that patients who received the combination of treatment A and PLD had more side effects, especially in their skin and mouth. However, the researchers noted that these side effects were manageable and didn't stop the patients from receiving the treatment.\n\nOverall, the study suggests that the combination of treatment A and PLD"
    },
    {
        "id": "56",
        "PMID": "20973267",
        "title": "Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer",
        "journal": "Int J Gynecol Cancer",
        "abstract": "Objective:\nTo evaluate the safety and efficacy of treatment A in combination with pegylated liposomal doxorubicin (PLD) in platinum\u2010resistant ovarian cancer (OC).\nMethods:\nPatients with platinum\u2010refractory or \u2010resistant primary or secondary) OC were randomized to receive treatment A and PLD at 50 mg/m2 intravenously or PLD alone at 50 mg/m2 intravenously on day 1 every 28 days until tumor progression or unacceptable toxicity. The primary end point was progression\u2010free survival (PFS). Other end points were objective response rate, and safety. The study was originally planned for 244 patients. The trial was temporarily placed on hold after 125 patients were randomized while the results of another trial were being reviewed and the sponsor decided not to resume enrollment. The interim analysis became the final analysis.\nResults:\nThe median PFS was 5.6 months for treatment A + PLD (n = 65) versus 3.7 months for PLD (n = 60) (hazards ratio, 0.92; P = 0.7243). ORR was 12.3% for treatment A + PLD vs. 8.3% for PLD, p=0.5640. Hematologic adverse events were 66% on the treatment A + PLD arm versus 44% on the PLD arm with neutropenia 40.0% vs. 22.8%; thrombopenia 33.8% vs. 7.0%; febrile neutropenia10.8% vs. 3.5%. Nonhematologic adverse events were similar for both arms. The incidence of palmar\u2010plantar erythrodysesthesia and stomatitis was lower on treatment A + PLD (23%, 31%, respectively) versus (39%, 49%, respectively) on PLD. The incidence of nausea and fatigue was higher in treatment A + PLD 60.0% vs. 49.1% and 43.1% vs. 36.8%).Thirteen deaths caused by serious adverse event were reported 7 with treatment A + PLD vs. 6 with PLD.\nConclusion:\nTreatment A in combination with pegylated liposomal doxorubicin was not more effective than pegylated liposomal doxorubicin alone in patients with platinum\u2010 resistant ovarian cancer. This study was registered at www.clinicaltrials.gov",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a new treatment called \"treatment A\" works better than another treatment called \"pegylated liposomal doxorubicin\" for people with a type of cancer called ovarian cancer. The study involved 244 patients who were divided into two groups: one group got treatment A and the other group got pegylated liposomal doxorubicin.\n\nThe study found that the two treatments were not very different in terms of how well they worked. The patients who got treatment A lived for about 5.6 months on average before their cancer got worse, while the patients who got pegylated liposomal doxorubicin lived for about 3.7 months on average.\n\nThe study also looked at how often patients experienced side effects from the treatments. The patients who got treatment A were more likely to experience side effects like low white blood cell counts, low platelet counts, and fever. However, the patients who got pegylated liposomal doxorubicin were more likely to experience side effects like skin rash and mouth sores.\n\nOverall, the study found that treatment A did not work any better than peg"
    },
    {
        "id": "25",
        "PMID": "21041710",
        "title": "Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nThis phase III trial assesses whether treatment A increases the duration of functional independence after surgery or radiosurgery of brain metastases.\nPatients and methods:\nPatients with one to three brain metastases of solid tumors (small\u2010cell lung cancer excluded) with stable systemic disease or asymptomatic primary tumors and WHO performance status (PS) of 0 to 2 were treated with complete surgery or radiosurgery and randomly assigned to treatment A or observation (OBS). The primary end point was time to WHO PS deterioration to more than 2.\nResults:\nOf 359 patients, 199 underwent radiosurgery, and 160 underwent surgery. In the radiosurgery group, 100 patients were allocated to OBS, and 99 were allocated to treatment A. After surgery, 79 patients were allocated to OBS, and 81 were allocated to treatment A. The median time to WHO PS more than 2 was 10.0 months (95% CI, 8.1 to 11.7 months) after OBS and 9.5 months (95% CI, 7.8 to 11.9 months) after treatment A (P = .71). Overall survival was similar in the treatment A and OBS arms (median, 10.9 v 10.7 months, respectively; P = .89). Treatment A reduced the 2\u2010year relapse rate both at initial sites (surgery: 59% to 27%, P < .001; radiosurgery: 31% to 19%, P = .040) and at new sites (surgery: 42% to 23%, P = .008; radiosurgery: 48% to 33%, P = .023). Salvage therapies were used more frequently after OBS than after treatment A. Intracranial progression caused death in 78 (44%) of 179 patients in the OBS arm and in 50 (28%) of 180 patients in the treatment A arm.\nConclusion:\nAfter radiosurgery or surgery of a limited number of brain metastases, treatment A reduces intracranial relapses and neurologic deaths but fails to improve the duration of functional independence and overall survival.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a new treatment can help people with cancer in their brains. The treatment is called \"treatment A.\" The study looked at how well the treatment worked in people who had surgery or radiation to remove the cancer in their brains.\n\nThe study found that the treatment helped reduce the number of times the cancer came back in the brain, and it also helped people live longer without their cancer getting worse. However, the treatment didn't make a big difference in how long the people lived overall.\n\nThe study also found that some people who didn't get the treatment (called \"observation\") lived just as long as those who did get the treatment. But, the people who got the treatment had fewer side effects than those who didn't get it.\n\nSo, the study showed that the treatment can be helpful in some ways, but it's not a cure-all for brain cancer. It's important to talk to a doctor to figure out the best treatment plan for each person.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "26",
        "PMID": "21041710",
        "title": "Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nThis phase III trial assesses whether treatment A increases the duration of functional independence after surgery or radiosurgery of brain metastases.\nPatients and methods:\nPatients with one to three brain metastases of solid tumors (small\u2010cell lung cancer excluded) with stable systemic disease or asymptomatic primary tumors and WHO performance status (PS) of 0 to 2 were treated with complete surgery or radiosurgery and randomly assigned to treatment A or observation (OBS). The primary end point was time to WHO PS deterioration to more than 2.\nResults:\nOf 359 patients, 179 were allocated to OBS (100 who underwent radiosurgery and 79 who underwent surgery) and 180 to treatment A (99 who underwent radiosurgery and 81 who underwent surgery). The median time to WHO PS more than 2 was 10.0 months (95% CI, 8.1 to 11.7 months) after OBS and 9.5 months (95% CI, 7.8 to 11.9 months) after treatment A (HR= 0.96; 95% CI (0.76\u20101.20); P = .71). Overall survival did not differ in the treatment A and OBS arms (median, 10.9 v 10.7 months, respectively; P = .89). Progression free survival was 4.6 months (95% CI, 3.9 to 6.1 months) in treatment A arm vs 3.4 months (95% CI, 3.1 to 3.9 months) in the OBS arm; p=.02. Extracranial progression at 2 years were 63% in the OBS arm vs. 65% in the treatment A arm; p=.73. Intracranial progression was 78% in the OBS arm vs. 48% in the treatment A arm; p<.001. 16 serious adverse events were reported; 13 in treatment A and 3 in OBS arm.\nConclusion:\nTreatment A was not more effective than observation for the primary and most secondary outcomes in patients with one to three brain metastases of solid tumors.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a special treatment helps people with cancer in their brains. The treatment was given to some people and not given to others, and the researchers looked at how well the treatment worked. They found out that the treatment didn't really help the people with cancer live longer or feel better. In fact, the people who didn't get the treatment lived just as long as the people who did get the treatment.\n\nThe researchers also looked at some other things, like how many people got better or worse after the treatment, and they found out that the treatment didn't make a big difference in those things either. So, the study found that the treatment didn't work very well for people with cancer in their brains.\n\nIt's important to remember that this study was done with a lot of people, and the results might not be the same for every person. But overall, the study showed that the treatment didn't work very well for most people with cancer in their brains.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "43",
        "PMID": "21060024",
        "title": "Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nWe examined the value of treatment A in a phase III trial with strict preoperative staging and surgical resection guidelines.\nPatients and methods:\nPatients with locally advanced adenocarcinoma of the stomach or esophagogastric junction (AEG II and III) were randomly assigned to treatment A followed by surgery or to surgery alone. To detect with 80% power an improvement in median survival from 17 months with surgery alone to 24 months with treatment A, 282 events were required.\nResults:\nThis trial was stopped for poor accrual after 144 patients were randomly assigned (72:72); 52.8% patients had tumors located in the proximal third of the stomach, including AEG type II and III. The International Union against Cancer R0 resection rate was 81.9% after treatment A as compared with 66.7% with surgery alone (P = .036). The surgery\u2010only group had more lymph node metastases than the treatment A group (76.5% v 61.4%; P = .018). Postoperative complications were more frequent in the treatment A arm (27.1% v 16.2%; P = .09). After a median follow\u2010up of 4.4 years and 67 deaths, a survival benefit could not be shown (hazard ratio, 0.84; 95% CI, 0.52 to 1.35; P = .466).\nConclusion:\nThis trial showed a significantly increased R0 resection rate but failed to demonstrate a survival benefit. Possible explanations are low statistical power, a high rate of proximal gastric cancer including AEG and/or a better outcome than expected after radical surgery alone due to the high quality of surgery with resections of regional lymph nodes outside the perigastic area (celiac trunc, hepatic ligament, lymph node at a. lienalis; D2).",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a new treatment could help people with cancer live longer. The treatment was given to some people and not given to others, and the researchers looked at how well the treatment worked. They found that some people who got the treatment had more of their cancer removed, but they didn't find any proof that the treatment made people live longer.\n\nThe researchers think that maybe the treatment wasn't strong enough, or maybe the people in the study were already doing pretty well without the treatment. They also think that it's possible that the doctors who did the surgery were really good at removing cancer, which could have made the difference.\n\nSo, even though the treatment didn't seem to help people live longer, the researchers are still happy about the results because they showed that the doctors are good at removing cancer. And that's important because it means that people with cancer can get the best possible care.\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "44",
        "PMID": "21060024",
        "title": "Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954",
        "journal": "J Clin Oncol",
        "abstract": "Purpose:\nWe examined the value of treatment A in a phase III trial with strict preoperative staging and surgical resection guidelines.\nPatients and methods:\nPatients with locally advanced adenocarcinoma of the stomach or esophagogastric junction (AEGII and III) were randomly assigned to treatment A followed by surgery or to surgery alone. The primary outcome was overall survival.\nResults:\nThis trial was stopped for poor accrual after 144 patients were randomly assigned (72:72); 52.8% patients had tumors located in the proximal third of the stomach, including AEG type II and III. After a median follow\u2010up of 4.4 years and 67 deaths, the median survival was 64.6 months (95% CI, 42.4 to NA) in the treatment A arm versus 52.5 month (95% CI 31.7 to NA) in the surgery alone arm (hazard ratio 0.84; 95% CI, 0.52 to 1.35; P = .466). The survival rate at 2 year was respectively 72.7% (95% CI, 60.7\u201081.7) and 69.9% (95% CI, 57.7\u201079.2) in the treatment A and surgery\u2010only arm. The HR for progression free survival was 0.76 (95% CI, 0.49\u2010 1.16; p=.20). The International Union against Cancer R0 resection rate was 81.9% after treatment A as compared with 66.7% with surgery alone (P = .036). The surgery\u2010only group had more lymph node metastases than the treatment A (76.5% v 61.4%; p = .018). Postoperative complications were more frequent in the treatment A arm (27.1% v 16.2%; P = .09).\nConclusion:\nTreatment A followed by surgery was not more effective than surgery alone on overall survival in patients with locally advanced cancer of the stomach.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a special treatment called \"treatment A\" helps people with cancer in their stomach or esophagus (the tube that takes food from your mouth to your stomach). The treatment involved doing the special treatment first, and then having surgery to remove the cancer. The doctors wanted to see if this way of doing things was better than just having surgery alone.\n\nThey looked at the results of the study and found out that the two groups of patients (the ones who had the special treatment first and the ones who just had surgery) didn't differ much in terms of how long they lived. The special treatment didn't seem to make a big difference in their overall survival.\n\nHowever, there were some other interesting things that the doctors found. They noticed that the group of patients who had the special treatment first had more of their cancer removed during surgery than the group that just had surgery alone. This means that the special treatment might have helped the doctors remove more of the cancer during surgery.\n\nBut, the doctors also found that the group of patients who had the special treatment first had more complications after surgery than the group that just had surgery alone. This means that the special treatment might"
    },
    {
        "id": "7",
        "PMID": "21399726",
        "title": "The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5)",
        "journal": "J Support Oncol",
        "abstract": "Sleep disorders are a substantial problem for cancer survivors, with prevalence estimates ranging from 23% to 61%. Although numerous prescription hypnotics are available, few are approved for long\u2010term use or have demonstrated benefit in this circumstance. Hypnotics may have unwanted side effects and are costly, and cancer survivors often wish to avoid prescription drugs. New options with limited side effects are needed. The purpose of this trial was to evaluate the efficacy of treatment A for sleep in people with cancer who were undergoing cancer treatment. Participants were randomized to receive treatment A or placebo orally 1 hour before bedtime for 8 weeks. The primary end point was area under the curve (AUC) of the overall Pittsburgh Sleep Quality Index (PSQI). Secondary outcomes included the Functional Outcomes of Sleep Questionnaire, the Brief Fatigue Inventory (BFI), and the Profile of Mood States (POMS). Toxicity was evaluated with both self\u2010reported numeric analogue scale questions and the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Questionnaires were completed at baseline and at 4 and 8 weeks. A total of 227 patients were randomized into this study between March 19, 2004, and March 9, 2007, with 119 being evaluable for the primary end point. The AUC over the 8 weeks for treatment A was 51.4 (SD = 16), while that for placebo was 49.7 (SD = 15), with a P value of 0.6957. A supplemental, exploratory analysis revealed that several fatigue end points, as measured by the BFI and POMS, were significantly better for those taking treatment A over placebo. Participants also reported less trouble with sleep and less drowsiness on treatment A than placebo. There were no significant differences in toxicities as measured by self\u2010report or the CTCAE except for mild alkaline phosphatase increases, which were slightly more common in the placebo group. This study failed to provide data to support the hypothesis that treatment A, at bedtime could improve sleep as measured by the PSQI. However, exploratory analyses revealed improvement in some secondary outcomes, such as fatigue. Further research with treatment A exploring physiologic effects in oncology symptom management may be warranted.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help!\n\nSo, there was a big study done to see if a special treatment could help people with cancer sleep better. The treatment was given to some people and not to others, and the researchers looked at how well they slept. They found out that the treatment didn't really help the people with cancer sleep better, but they did find out that the treatment made some people feel less tired and less sleepy.\n\nThe researchers also looked at some other things, like how often people got sick or had side effects from the treatment. They found out that the treatment was safe and didn't cause any big problems, but some people did have a little bit of nausea.\n\nOverall, the study didn't show that the treatment helped people with cancer sleep better, but it did give some clues about how the treatment might be useful for other things. The researchers think they might want to do more studies to see if the treatment is helpful for other things, like managing symptoms.\n\nSo, the study didn't find what it was looking for, but it still gave some useful information that might help doctors and patients in the future."
    },
    {
        "id": "8",
        "PMID": "21399726",
        "title": "The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5)",
        "journal": "J Support Oncol",
        "abstract": "Sleep disorders are a substantial problem for cancer survivors, with prevalence estimates ranging from 23% to 61%. Although numerous prescription hypnotics are available, few are approved for long\u2010term use or have demonstrated benefit in this circumstance. Hypnotics may have unwanted side effects and are costly, and cancer survivors often wish to avoid prescription drugs. New options with limited side effects are needed. The purpose of this trial was to evaluate the efficacy of a treatment A for sleep in people with cancer who were undergoing cancer treatment. Participants were randomized to receive treatment A or placebo orally 1 hour before bedtime for 8 weeks. The primary end point was area under the curve (AUC) of the overall Pittsburgh Sleep Quality Index (PSQI). Secondary outcomes included the Functional Outcomes of Sleep Questionnaire, the Brief Fatigue Inventory (BFI), and the Profile of Mood States (POMS). Toxicity was evaluated with both self\u2010reported numeric analogue scale questions and the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. Questionnaires were completed at baseline and at 4 and 8 weeks. A total of 227 patients were randomized into this study between March 19, 2004, and March 9, 2007. Twenty\u2010three patients withdrew before starting the study treatment. Primary end\u2010point data were available on 119 patients (62 receiving treatment A and 57 receiving placebo). Baseline characteristics and baseline patient reported outcomes were well balanced between arms. The AUC over the 8 weeks for treatment A was 51.4 (SD = 16 and for placebo was 49.7 (SD = 15), with a P value of 0.7. The FOSQ was not statistically significantly different between groups. There was no statistically significant difference between groups for the POMS week 8 treatment A 6.9 vs. placebo 6.0; p=0.90. For the BFI at week 8 the treatment A and placebo arm scored respectively for fatigue now 22.1 vs. 10.5; p<0.01; for usual fatigue 19.4 vs. 10.0; p=0.05; for worst fatigue 14.8 vs. 12.4; p=0.65; and for activity inference 12.3 vs. 10.8; p=0.75.There were no significant differences in toxicities as measured by self\u2010report or the CTCAE. Treatment A was not more effective than placebo on sleep quality in patients who were undergoing cancer treatment.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help!\n\nThe study you mentioned looked at a new treatment for people with cancer who were having trouble sleeping. The treatment was given to some patients and a placebo (a pretend treatment) was given to other patients. The researchers wanted to see if the treatment helped improve the patients' sleep quality.\n\nThey found out that the treatment did not work any better than the placebo in helping patients sleep better. The study also looked at some other things, like how tired the patients were and how they felt about their sleep, but the treatment did not make a big difference in those areas either.\n\nOverall, the study found that the new treatment was not more effective than the placebo in helping cancer patients sleep better.\n\nHere's a summary of the study in simpler language:\n\nThe study looked at a new medicine to help people with cancer sleep better. They gave some people the medicine and others a pretend medicine. They found out that the medicine didn't work any better than the pretend medicine in helping people sleep better. They also looked at how tired people were and how they felt about their sleep, but the medicine didn't make a big difference in those areas either. So, the study found that the new medicine isn't more effective than the pretend medicine in helping cancer patients sleep better."
    },
    {
        "id": "5",
        "PMID": "21471562",
        "title": "Impact of a novel nurse-led prechemotherapy education intervention (ChemoEd) on patient distress, symptom burden, and treatment-related information and support needs: results from a randomised, controlled trial",
        "journal": "Ann Oncol",
        "abstract": "Background: \nHigh levels of distress and need for self\u2010care information by patients commencing chemotherapy suggest that current prechemotherapy education is suboptimal. We conducted a randomized, controlled trial of a prechemotherapy education intervention (treatment A) to assess impact on patient distress, treatment\u2010related concerns, and the prevalence and severity of and bother caused by six chemotherapy side\u2010effects.\nPatients and methods:\nOne hundred and ninety\u2010two breast, gastrointestinal, and haematologic cancer patients were recruited before the trial closing prematurely (original target 352). Treatment A was administered before first treatment (intervention 1), 48 h after first treatment (intervention 2), and immediately before second treatment (intervention 3). Patient outcomes were measured at baseline (T1: pre\u2010education) and immediately preceding treatment cycles 1 (T2) and 3 (T3).\nResults:\nTreatment A did not significantly reduce patient distress. However, a significant decrease in sensory/psychological (P=0.027) and procedural (P=0.03) concerns, as well as prevalence and severity of and bother due to vomiting (all P=0.001), were observed at T3. In addition, subgroup analysis of patients with elevated distress at T1 indicated a significant decrease (P=0.035) at T2 but not at T3 (P=0.055) in treatment A patients.\nConclusion:\nTreatment A holds promise to improve patient treatment\u2010related concerns and some physical/psychological outcomes; however, further research is required on more diverse patient populations to ensure generalisability.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help!\n\nSo, there was a big study about cancer treatment. Researchers wanted to see if a special education program could help people feel less stressed and worried about their treatment. They tested this program on 192 people with different types of cancer, like breast, stomach, and blood cancer.\n\nThe program had three parts, and the researchers gave it to the patients at different times. They measured how the patients felt before, during, and after their treatment.\n\nThe results were interesting! The program didn't completely eliminate the patients' stress, but it did help them feel less worried about some of the side effects of their treatment, like feeling sick or having trouble breathing. The program also helped some patients feel less anxious about their treatment in general.\n\nHowever, the researchers found that the program didn't help all patients equally. Some patients who were very stressed at the beginning of the study saw some improvement after the program, but others didn't.\n\nOverall, the study suggests that this education program might be helpful for some cancer patients, but more research is needed to see if it works for everyone. It's important to remember that cancer treatment can be tough, but there are always new ways to make it easier and less scary."
    },
    {
        "id": "6",
        "PMID": "21471562",
        "title": "Impact of a novel nurse-led prechemotherapy education intervention (ChemoEd) on patient distress, symptom burden, and treatment-related information and support needs: results from a randomised, controlled trial",
        "journal": "Ann Oncol",
        "abstract": "Background:\nHigh levels of distress and need for self\u2010care information by patients commencing chemotherapy suggest that current prechemotherapy education is suboptimal. We conducted a randomized, controlled trial of a prechemotherapy education intervention (treatment A) to assess impact on patient distress.\nPatients and methods:\nOne hundred and ninety\u2010two breast, gastrointestinal, and haematologic cancer patients were recruited before the trial closing prematurely (original target 352). Treatment A was administered before first treatment (intervention 1), 48 h after first treatment (intervention 2), and immediately before second treatment (intervention 3). Patient outcomes were measured at baseline (T1: pre\u2010education) and immediately preceding treatment cycles 1 (T2) and 3 (T3). The primary endpoint was psychological distress at T2 and T3 as measured by the HADS.\nResults:\nAt T2 and T3 treatment A did not significantly reduce patients distress with mean (SD) HADS scores respectively for routine care vs. treatment A at T2 10.9 (6.8) vs. 9.9 (5.8); p=0.33; and T3 10.4 (7.0) vs. 9.0 (5.8), p=0.15. There was a statistically significant decrease in sensory/psychological (P=0.027) and procedural (P=0.03) concerns, but there was no statistically significant difference between groups for the prevalence, severity and bother of most chemotherapy side\u2010effects (nausea, infection, hair loss, mouth and throat problem and fatigue) except vomiting at T3.\nConclusion:\nTreatment A was not more effective than usual care in patients commencing chemotherapy.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study about cancer patients who were getting chemotherapy. Some of these patients needed help dealing with the stress and side effects of chemotherapy, so the doctors tried something called \"treatment A\" to see if it would help. They looked at how well treatment A worked by measuring how much stress the patients were feeling before, during, and after chemotherapy.\n\nUnfortunately, the study found that treatment A didn't really help the patients feel less stressed. In fact, the patients who got treatment A didn't feel any different than the patients who didn't get it. The doctors were a little disappointed, but they learned something important from the study. They learned that there are other things they can try to help patients feel better during chemotherapy.\n\nSo, even though treatment A didn't work as well as they hoped, the doctors are still trying to find ways to make chemotherapy easier for patients. And that's a good thing!\n\nI hope that helps! Let me know if you have any other questions."
    },
    {
        "id": "47",
        "PMID": "22112969",
        "title": "Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer",
        "journal": "Ann Oncol",
        "abstract": "Background:\nTreatment A, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration\u2010resistant prostate cancer (mCRPC). A randomized, double\u2010blind, placebo\u2010controlled phase II trial compared DP combined with either treatment A (A) or placebo in chemonaive mCRPC.\nPatients and methods:\nMen with progressive mCRPC despite androgen deprivation were eligible and randomized 1:1. Patients received docetaxel (75 mg/m2 day 1) and prednisone 5 mg orally twice daily every 21 days with either treatment A or placebo twice daily orally on days 1\u20103. The primary end point was overall survival (OS).\nResults:\nTwo hundred and twenty\u2010one patients were randomly assigned. Median OS for treatment A plus docetaxel\u2010prednisone (ADP) and placebo\u2010DP was 18.1 versus 17.8 months [hazard ratio (HR) 1.07, 95% confidence interval 0.72\u20101.55, P=0.63]. Secondary end points were also not statistically different. Grade 3/4 toxic effects for ADP versus placebo\u2010DP were cardiac events (5% versus 2%), lymphopenia (23% versus 16%), neutropenia (47% versus 40%), ileus (2% versus 0%) and pulmonary embolism (6% versus 2%). In a subgroup of high\u2010risk mCRPC (n=34), outcomes appeared to favor ADP (median OS 19 versus 14 months).\nConclusion:\nTreatment A was tolerable but did not extend OS when combined with DP in mCRPC; a potential benefit was observed in high\u2010risk patients.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a new treatment called \"Treatment A\" could help people with a type of cancer called \"metastatic castration-resistant prostate cancer\" (mCRPC). The study involved giving some patients a combination of three things: \"docetaxel\" (which is a type of medicine that helps shrink tumors), \"prednisone\" (which is a type of medicine that helps reduce swelling), and \"Treatment A\" (which is a special combination of other medicines).\n\nThe study found that the combination of these three things did not really help the patients live longer. In fact, the patients who got the combination of docetaxel, prednisone, and Treatment A did not live any longer than the patients who just got the other two medicines (docetaxel and prednisone) without Treatment A.\n\nBut, the study also found that when the researchers looked at a smaller group of patients who were considered \"high-risk,\" the combination of docetaxel, prednisone, and Treatment A seemed to help those patients live longer.\n\nSo, the study showed that Treatment A might be helpful for some patients with mCRPC"
    },
    {
        "id": "48",
        "PMID": "22112969",
        "title": "Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer",
        "journal": "Ann Oncol",
        "abstract": "Background:\nTreatment A, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration\u2010resistant prostate cancer (mCRPC). A randomized, double\u2010blind, placebo\u2010controlled phase II trial compared DP combined with either treatment A (A) or placebo in chemonaive mCRPC.\nPatients and methods:\nMen with progressive mCRPC despite androgen deprivation were eligible and randomized 1:1. Patients received docetaxel (75 mg/m2 day 1) and prednisone 5 mg orally twice daily every 21 days with either treatment A or placebo twice daily orally on days 1\u20103. The primary end point was overall survival (OS).\nResults:\nTwo hundred and twenty\u2010one patients were randomly assigned. Median OS for treatment A plus docetaxel\u2010prednisone (ADP) and placebo\u2010DP was 18.1 versus 17.8 months [hazard ratio (HR) 1.07, 95% confidence interval 0.72\u20101.55, P=0.63]. Secondary end points were also not statistically different. Grade 3/4 toxic effects for ADP versus placebo\u2010DP were cardiac events (5% versus 2%), lymphopenia (23% versus 16%), neutropenia (47% versus 40%), ileus (2% versus 0%) and pulmonary embolism (6% versus 2%). In a subgroup of high\u2010risk mCRPC (n=34), outcomes appeared to favor ADP (median OS 19 versus 14 months).\nConclusion:\nTreatment A was not more effective than placebo in metastatic castration\u2010 resistant prostate cancer patients.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done to see if a new treatment called \"Treatment A\" could help people with a type of cancer called \"metastatic castration-resistant prostate cancer.\" The study involved giving some patients Treatment A, and some patients a pretend treatment called \"placebo.\" The researchers wanted to see if Treatment A was more effective than the placebo in helping these patients live longer.\n\nThe study found that Treatment A did not help these patients live longer than the placebo. In fact, the patients who got Treatment A did not live any longer than the patients who got the placebo. The study also looked at some other things, like how often patients got sick or had certain side effects, and found that Treatment A caused more side effects than the placebo.\n\nSo, the study showed that Treatment A is not a good treatment for metastatic castration-resistant prostate cancer. It's important to remember that this study only looked at a small group of patients, and more research is needed to find the best treatment for this type of cancer. But for now, doctors will have to keep looking for other treatments that can help these patients live longer and feel better.\n\nI hope"
    },
    {
        "id": "13",
        "PMID": "9093724",
        "title": "Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group",
        "journal": "Ann Oncol",
        "abstract": "Purpose:\nA phase III study was performed in patients with metastatic breast cancer (MBC) to evaluate the effect on response rate and survival of a treatment A.\nPatients and methods:\nFour hundred fifty\u2010six patients were randomized to receive either treatment A or comparator B in combination with 5\u2010FU (500 mg/m2) and cyclophosphamide (500 mg/m2) i.v., every 21 days for a maximum of six cycles (eight in case of CR).\nResults:\nOf 456 patients, 390 were evaluable for efficacy. Objective response (CR + PR) was seen in 57% (treatment A) vs. 41% (comparator B) of the evaluable patients (P = 0.003). The CR rate was higher in the treatment A arm (12% vs. 7%, P = 0.07). Treatment A produced significantly higher response rates in patients with visceral localization (50% vs. 34%, P = 0.011) and in patients with more than two metastatic organ sites (64% vs. 37%, P = 0.001). Median time to progression (7.6 vs. 7 months) and overall survival (18 months vs. 17 months) were similar. Myelosuppression was the principal toxic effect, with grade IV neutropenia observed in 57% of the patients treated with treatment A vs. 9% of those on comparator B. Grade IV infection or febrile neutropenia were observed in 8% (treatment A) vs. 0.4% (comparator B), but the incidence of septic death was the same in the two arms (two patients each). Cardiac toxicity was similar in the two treatment groups, with 5% vs. 3% of the patients taken off study due to cardiac events, primarily due to a decline in LVEF. Only three patients (two in treatment A) experienced congestive heart failure.\nConclusion:\nThis trial shows that treatment A can be administered for repeated cycles without bone marrow support with increased, though acceptable, toxicity and with a significant increase of antitumor effect (especially in visceral and/or high\u2010burden disease), but no increased survival.",
        "abstract_type": "spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done with a bunch of people who had a type of cancer called breast cancer. The study was trying to see if a new treatment would work better than an old treatment. The new treatment was given to 456 people, and the old treatment was given to 456 other people.\n\nThe study found that the new treatment made the cancer go away for a lot more people than the old treatment. Specifically, 57% of the people who got the new treatment had their cancer go away, compared to 41% of the people who got the old treatment.\n\nBut here's the thing: the study also found that the new treatment made some people feel sick more often than the old treatment. For example, 57% of the people who got the new treatment had a low white blood cell count, which can make them more likely to get an infection. And 8% of the people who got the new treatment had a serious infection.\n\nSo, even though the new treatment worked better than the old treatment, it also made some people feel sick more often. The study authors think that this is something doctors should keep in mind when deciding which treatment to use.\n\nIn plain language, the study showed that a new treatment for breast cancer"
    },
    {
        "id": "14",
        "PMID": "9093724",
        "title": "Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group",
        "journal": "Ann Oncol",
        "abstract": "Purpose:\nA phase III study was performed in patients with metastatic breast cancer (MBC) to evaluate the effect on response rate and survival of a treatment A.\nPatients and methods:\nFour hundred fifty\u2010six patients were randomized to receive either treatment A or comparator B in combination with 5\u2010FU (500 mg/m2) and cyclophosphamide (500 mg/m2) i.v., every 21 days for a maximum of six cycles (eight in case of CR). The primary outcome was overall survival.\nResults:\nOf 456 patients randomized to treatment A (214) or comparator B (242), 390 were evaluable for efficacy (treatment A 182, comparator B 208). There was no statistically significant difference between the 2 groups for the primary outcome with a median survival of 18 and 17 months, respectively for treatment A and comparator B (P = 0.54). Objective response (CR + PR) was seen in 57% (treatment A) vs. 41% (comparator B) of the evaluable patients (P = 0.003). The median duration of response was 9.1 months on treatment A and 9.3 on comparator B, the median Time to Treatment Failure (TTF) was, respectively, 5.8 vs. 5.3 months (P = 0.7). Myelosuppression was the principal toxic effect, with grade IV neutropenia observed in 57% of the patients treated with treatment A vs. 9% of those on comparator B. Grade IV infection or febrile neutropenia were observed in 8% (treatment A) vs. 0.4% (comparator B), but the incidence of septic death was the same in the two arms (two patients each). Cardiac toxicity was similar in the two treatment groups, with 5% vs. 3% of the patients taken off study due to cardiac events, primarily due to a decline in LVEF. Three patients (two in treatment A) experienced congestive heart failure.\nConclusion:\nTreatment A was not more effective than comparator B in patients with metastatic breast cancer.",
        "abstract_type": "no_spin",
        "plain_language_summary": " Sure, I'd be happy to help you summarize the abstract in a way that a fifth grader can understand!\n\nSo, there was a big study done with 456 people who had a type of cancer called breast cancer. The study wanted to see if one treatment worked better than another treatment. The two treatments were given to the patients in different ways, and the researchers looked at how well they worked.\n\nThe results showed that the two treatments were about the same in terms of how well they worked. Only a small difference was found between the two groups of patients. The study found that about 57% of the patients who got one treatment had a good response to it, compared to about 41% of the patients who got the other treatment.\n\nHowever, there were some side effects to one of the treatments. A lot of patients who got that treatment had a low white blood cell count, which can make them more likely to get an infection. A small number of patients also had heart problems.\n\nOverall, the study found that the two treatments were about the same in terms of how well they worked, but one of the treatments had more side effects.\n\nSo, in plain language, the study showed that the two treatments were not much different from each other in terms of how well they worked, but one of the treatments had more side effects."
    }
]